JP2009507080A - Axl阻害剤として有用なトリアゾール誘導体 - Google Patents
Axl阻害剤として有用なトリアゾール誘導体 Download PDFInfo
- Publication number
- JP2009507080A JP2009507080A JP2008530213A JP2008530213A JP2009507080A JP 2009507080 A JP2009507080 A JP 2009507080A JP 2008530213 A JP2008530213 A JP 2008530213A JP 2008530213 A JP2008530213 A JP 2008530213A JP 2009507080 A JP2009507080 A JP 2009507080A
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- amino
- group
- alkyl
- triazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 title abstract description 4
- 239000003112 inhibitor Substances 0.000 title description 3
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 11
- 230000000694 effects Effects 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 559
- -1 cyano, nitro, oxo, thioxo, trimethylsilanyl Chemical group 0.000 claims description 385
- 125000001188 haloalkyl group Chemical group 0.000 claims description 378
- 239000001257 hydrogen Substances 0.000 claims description 367
- 229910052739 hydrogen Inorganic materials 0.000 claims description 367
- 125000001072 heteroaryl group Chemical group 0.000 claims description 366
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 356
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 329
- 125000000623 heterocyclic group Chemical group 0.000 claims description 320
- 125000005843 halogen group Chemical group 0.000 claims description 315
- 125000001424 substituent group Chemical group 0.000 claims description 307
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 257
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 222
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 219
- 125000003118 aryl group Chemical group 0.000 claims description 207
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 200
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 176
- 125000003107 substituted aryl group Chemical group 0.000 claims description 170
- 125000002947 alkylene group Chemical group 0.000 claims description 163
- 125000004450 alkenylene group Chemical group 0.000 claims description 159
- 150000001875 compounds Chemical class 0.000 claims description 135
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 128
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 115
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims description 113
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 107
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 99
- 125000003342 alkenyl group Chemical group 0.000 claims description 96
- 125000000304 alkynyl group Chemical group 0.000 claims description 94
- 125000004043 oxo group Chemical group O=* 0.000 claims description 84
- 125000005312 heteroarylalkynyl group Chemical group 0.000 claims description 82
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 79
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 79
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 claims description 78
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 claims description 77
- 229910052757 nitrogen Inorganic materials 0.000 claims description 64
- 125000004419 alkynylene group Chemical group 0.000 claims description 58
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 58
- 125000005357 cycloalkylalkynyl group Chemical group 0.000 claims description 50
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 39
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims description 23
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 19
- 239000000651 prodrug Substances 0.000 claims description 18
- 229940002612 prodrug Drugs 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 15
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 14
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 10
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 10
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 6
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 6
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 201000009273 Endometriosis Diseases 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 125000001401 1,2,4-triazol-4-yl group Chemical group N=1N=C([H])N([*])C=1[H] 0.000 claims description 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims description 3
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 3
- 125000006189 4-phenyl benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 150000001204 N-oxides Chemical class 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000024248 Vascular System injury Diseases 0.000 claims description 3
- 208000012339 Vascular injury Diseases 0.000 claims description 3
- PWIGYBONXWGOQE-UHFFFAOYSA-N alizarin complexone Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=C(CN(CC(O)=O)CC(=O)O)C(O)=C2O PWIGYBONXWGOQE-UHFFFAOYSA-N 0.000 claims description 3
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- 125000000068 chlorophenyl group Chemical group 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 208000025113 myeloid leukemia Diseases 0.000 claims description 3
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 208000002177 Cataract Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010047571 Visual impairment Diseases 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 208000029257 vision disease Diseases 0.000 claims description 2
- 230000004393 visual impairment Effects 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 198
- XTMRUJFITBKHKF-UHFFFAOYSA-N O=C=C1NC=NN1 Chemical compound O=C=C1NC=NN1 XTMRUJFITBKHKF-UHFFFAOYSA-N 0.000 claims 9
- NHAZGSRLKBTDBF-UHFFFAOYSA-N 1,2,4-triazol-1-amine Chemical compound NN1C=NC=N1 NHAZGSRLKBTDBF-UHFFFAOYSA-N 0.000 claims 6
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 6
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- ZORDVGLUJGYQHC-UHFFFAOYSA-N (3-amino-1,2,4-triazol-1-yl)-(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)N2N=C(N)N=C2)=C1 ZORDVGLUJGYQHC-UHFFFAOYSA-N 0.000 claims 3
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 3
- HPTBXUZCYQBJJP-UHFFFAOYSA-N 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-isocyanato-1,2,4-triazole Chemical compound C(=O)=NN1N=C(N=C1)C1=CC2=C(OCCO2)C=C1 HPTBXUZCYQBJJP-UHFFFAOYSA-N 0.000 claims 2
- UAJVBJHJSGNUDP-UHFFFAOYSA-N O=C=C1NNC(NC=2C=CC(OCCN3CCCC3)=CC=2)=N1 Chemical compound O=C=C1NNC(NC=2C=CC(OCCN3CCCC3)=CC=2)=N1 UAJVBJHJSGNUDP-UHFFFAOYSA-N 0.000 claims 2
- DUNODFUDHXGRMR-UHFFFAOYSA-N O=C=C1NNC(NC=2C=CC(OCCN3CCCCC3)=CC=2)=N1 Chemical compound O=C=C1NNC(NC=2C=CC(OCCN3CCCCC3)=CC=2)=N1 DUNODFUDHXGRMR-UHFFFAOYSA-N 0.000 claims 2
- QTHWVDYFXXHCKO-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[4-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound C1=CC(OC(C)(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCC3)=CC=2)=N1 QTHWVDYFXXHCKO-UHFFFAOYSA-N 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 230000005740 tumor formation Effects 0.000 claims 2
- QGIAQCGAUXRCQN-UHFFFAOYSA-N (2-chlorophenyl)-[2,5-diamino-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-3H-1,2,4-triazol-1-yl]methanone Chemical compound NC1=NC(N(N1C(=O)C1=C(C=CC=C1)Cl)N)C1=CC2=C(OCCO2)C=C1 QGIAQCGAUXRCQN-UHFFFAOYSA-N 0.000 claims 1
- UMZSCTIOTGRPNG-UHFFFAOYSA-N (3-chlorophenyl)-[2,5-diamino-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-3H-1,2,4-triazol-1-yl]methanone Chemical compound NC1=NC(N(N1C(=O)C1=CC(=CC=C1)Cl)N)C1=CC2=C(OCCO2)C=C1 UMZSCTIOTGRPNG-UHFFFAOYSA-N 0.000 claims 1
- PNZPNYODHVFLRC-UHFFFAOYSA-N (4-chlorophenyl)-[2,5-diamino-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-3H-1,2,4-triazol-1-yl]methanone Chemical compound NC1=NC(N(N1C(=O)C1=CC=C(C=C1)Cl)N)C1=CC2=C(OCCO2)C=C1 PNZPNYODHVFLRC-UHFFFAOYSA-N 0.000 claims 1
- NRFGIUAJIAWVSM-UHFFFAOYSA-N 1-[2-[4-[[5-amino-1-(3-morpholin-4-ylbenzoyl)-1,2,4-triazol-3-yl]amino]phenoxy]ethyl]pyrrolidin-2-one Chemical compound N=1N(C(=O)C=2C=C(C=CC=2)N2CCOCC2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1=O NRFGIUAJIAWVSM-UHFFFAOYSA-N 0.000 claims 1
- IHMXXMVGQXHFTN-UHFFFAOYSA-N 1-[2-[4-[[5-amino-1-(4-morpholin-4-ylbenzoyl)-1,2,4-triazol-3-yl]amino]phenoxy]ethyl]pyrrolidin-2-one Chemical compound N=1N(C(=O)C=2C=CC(=CC=2)N2CCOCC2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1=O IHMXXMVGQXHFTN-UHFFFAOYSA-N 0.000 claims 1
- XCPODFGJDNBJIR-UHFFFAOYSA-N 1-[2-[4-[[5-amino-1-(4-propan-2-yloxybenzoyl)-1,2,4-triazol-3-yl]amino]phenoxy]ethyl]pyrrolidin-2-one Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3C(CCC3)=O)=CC=2)=N1 XCPODFGJDNBJIR-UHFFFAOYSA-N 0.000 claims 1
- STPJYJRCCBVRDB-UHFFFAOYSA-N 1-[2-[4-[[5-amino-1-[4-(thiadiazol-4-yl)benzoyl]-1,2,4-triazol-3-yl]amino]phenoxy]ethyl]pyrrolidin-2-one Chemical compound N=1N(C(=O)C=2C=CC(=CC=2)C=2N=NSC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1=O STPJYJRCCBVRDB-UHFFFAOYSA-N 0.000 claims 1
- QCLROQCLVYUOBI-UHFFFAOYSA-N 1-[2-[4-[[5-amino-1-[4-[(2-methylpropan-2-yl)oxy]benzoyl]-1,2,4-triazol-3-yl]amino]phenoxy]ethyl]pyrrolidin-2-one Chemical compound C1=CC(OC(C)(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3C(CCC3)=O)=CC=2)=N1 QCLROQCLVYUOBI-UHFFFAOYSA-N 0.000 claims 1
- DXMODMWMLNYQAH-UHFFFAOYSA-N 2-[3-[[5-amino-1-(2-methylbenzoyl)-1,2,4-triazol-3-yl]amino]phenoxy]acetonitrile Chemical compound CC1=CC=CC=C1C(=O)N1C(N)=NC(NC=2C=C(OCC#N)C=CC=2)=N1 DXMODMWMLNYQAH-UHFFFAOYSA-N 0.000 claims 1
- RIXUNLLOBWWNHG-UHFFFAOYSA-N 2-[3-[[5-amino-1-(3-methylbenzoyl)-1,2,4-triazol-3-yl]amino]phenoxy]-n-cyclohexylacetamide Chemical compound CC1=CC=CC(C(=O)N2C(=NC(NC=3C=C(OCC(=O)NC4CCCCC4)C=CC=3)=N2)N)=C1 RIXUNLLOBWWNHG-UHFFFAOYSA-N 0.000 claims 1
- XJRWFNSWOOWKFM-UHFFFAOYSA-N 2-[3-[[5-amino-1-(3-methylbenzoyl)-1,2,4-triazol-3-yl]amino]phenoxy]-n-methylacetamide Chemical compound CNC(=O)COC1=CC=CC(NC2=NN(C(N)=N2)C(=O)C=2C=C(C)C=CC=2)=C1 XJRWFNSWOOWKFM-UHFFFAOYSA-N 0.000 claims 1
- VSUSEMIMJXCYLF-UHFFFAOYSA-N 2-[3-[[5-amino-1-(3-methylbenzoyl)-1,2,4-triazol-3-yl]amino]phenoxy]acetonitrile Chemical compound CC1=CC=CC(C(=O)N2C(=NC(NC=3C=C(OCC#N)C=CC=3)=N2)N)=C1 VSUSEMIMJXCYLF-UHFFFAOYSA-N 0.000 claims 1
- GIADVRXJCAKMTN-UHFFFAOYSA-N 2-[3-[[5-amino-1-(4-methylbenzoyl)-1,2,4-triazol-3-yl]amino]phenoxy]acetonitrile Chemical compound C1=CC(C)=CC=C1C(=O)N1C(N)=NC(NC=2C=C(OCC#N)C=CC=2)=N1 GIADVRXJCAKMTN-UHFFFAOYSA-N 0.000 claims 1
- HRDAREHLSSSHBT-UHFFFAOYSA-N 2-[3-[[5-amino-1-(4-propan-2-yloxybenzoyl)-1,2,4-triazol-3-yl]amino]phenoxy]acetonitrile Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=C(OCC#N)C=CC=2)=N1 HRDAREHLSSSHBT-UHFFFAOYSA-N 0.000 claims 1
- KTQVEJGFDVZXDD-UHFFFAOYSA-N 2-[3-[[5-amino-2-(3-methylbenzoyl)-1,2,4-triazol-3-yl]amino]phenoxy]-n-cyclohexylacetamide Chemical compound CC1=CC=CC(C(=O)N2C(=NC(N)=N2)NC=2C=C(OCC(=O)NC3CCCCC3)C=CC=2)=C1 KTQVEJGFDVZXDD-UHFFFAOYSA-N 0.000 claims 1
- NCJZUMFNIHRNPJ-UHFFFAOYSA-N 2-[4-[[5-amino-1-(4-propan-2-yloxybenzoyl)-1,2,4-triazol-3-yl]amino]phenoxy]acetonitrile Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCC#N)=CC=2)=N1 NCJZUMFNIHRNPJ-UHFFFAOYSA-N 0.000 claims 1
- VZOUJKBRNNSEGL-UHFFFAOYSA-N 3-[[5-amino-1-(1h-indole-6-carbonyl)-1,2,4-triazol-3-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound C1=C2C=CNC2=CC(C(=O)N2C(N)=NC(=N2)NC2C3CC(C=C3)C2C(=O)N)=C1 VZOUJKBRNNSEGL-UHFFFAOYSA-N 0.000 claims 1
- SZCMEIUZIVDZKU-UHFFFAOYSA-N 3-[[5-amino-1-(4-propan-2-yloxybenzoyl)-1,2,4-triazol-3-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC2C(C3CC2C=C3)C(N)=O)=N1 SZCMEIUZIVDZKU-UHFFFAOYSA-N 0.000 claims 1
- OQQWRMVCEJFSBE-UHFFFAOYSA-N 3-[[5-amino-1-[3-(dimethylamino)benzoyl]-1,2,4-triazol-3-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CN(C)C1=CC=CC(C(=O)N2C(=NC(NC3C(C4CC3C=C4)C(N)=O)=N2)N)=C1 OQQWRMVCEJFSBE-UHFFFAOYSA-N 0.000 claims 1
- GRZCEOUYNCPZJG-UHFFFAOYSA-N 3-[[5-amino-1-[4-(dimethylamino)benzoyl]-1,2,4-triazol-3-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound C1=CC(N(C)C)=CC=C1C(=O)N1C(N)=NC(NC2C(C3CC2C=C3)C(N)=O)=N1 GRZCEOUYNCPZJG-UHFFFAOYSA-N 0.000 claims 1
- CYXNUEGTPOTDHD-UHFFFAOYSA-N 3-[[5-amino-2-(1h-indole-6-carbonyl)-1,2,4-triazol-3-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound C1=C2C=CNC2=CC(C(=O)N2N=C(N)N=C2NC2C3CC(C=C3)C2C(=O)N)=C1 CYXNUEGTPOTDHD-UHFFFAOYSA-N 0.000 claims 1
- NOHPLIRXGAGHEQ-UHFFFAOYSA-N 3-[[5-amino-2-(4-propan-2-yloxybenzoyl)-1,2,4-triazol-3-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(NC2C(C3CC2C=C3)C(N)=O)=NC(N)=N1 NOHPLIRXGAGHEQ-UHFFFAOYSA-N 0.000 claims 1
- BTNRXORWAUSFNH-UHFFFAOYSA-N 3-[[5-amino-2-[3-(dimethylamino)benzoyl]-1,2,4-triazol-3-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CN(C)C1=CC=CC(C(=O)N2C(=NC(N)=N2)NC2C(C3CC2C=C3)C(N)=O)=C1 BTNRXORWAUSFNH-UHFFFAOYSA-N 0.000 claims 1
- MKKKMNSNNKBPNA-UHFFFAOYSA-N 3-[[5-amino-2-[4-(dimethylamino)benzoyl]-1,2,4-triazol-3-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound C1=CC(N(C)C)=CC=C1C(=O)N1C(NC2C(C3CC2C=C3)C(N)=O)=NC(N)=N1 MKKKMNSNNKBPNA-UHFFFAOYSA-N 0.000 claims 1
- FHHQLWMLTNNLPW-UHFFFAOYSA-N 3-amino-n-(1,3-benzodioxol-5-yl)-5-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound C=1C=C2OCOC2=CC=1NC(=O)N1N=C(N)N=C1NC(C=C1)=CC=C1OCCN1CCCCC1 FHHQLWMLTNNLPW-UHFFFAOYSA-N 0.000 claims 1
- XPWWFEIYDZXDGX-UHFFFAOYSA-N 3-amino-n-(3,5-dimethoxyphenyl)-5-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound COC1=CC(OC)=CC(NC(=O)N2C(=NC(N)=N2)NC=2C=CC(OCCN3CCCCC3)=CC=2)=C1 XPWWFEIYDZXDGX-UHFFFAOYSA-N 0.000 claims 1
- PAKVXTXEMKZLGR-UHFFFAOYSA-N 3-amino-n-(3-methylphenyl)-5-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound CC1=CC=CC(NC(=O)N2C(=NC(N)=N2)NC=2C=CC(OCCN3CCCCC3)=CC=2)=C1 PAKVXTXEMKZLGR-UHFFFAOYSA-N 0.000 claims 1
- QEOMQUZNUXBEDX-UHFFFAOYSA-N 3-amino-n-(4-butoxyphenyl)-5-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound C1=CC(OCCCC)=CC=C1NC(=O)N1C(NC=2C=CC(OCCN3CCCCC3)=CC=2)=NC(N)=N1 QEOMQUZNUXBEDX-UHFFFAOYSA-N 0.000 claims 1
- RZUJWQSMYGJDRX-UHFFFAOYSA-N 3-amino-n-(4-methoxyphenyl)-5-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)N1C(NC=2C=CC(OCCN3CCCCC3)=CC=2)=NC(N)=N1 RZUJWQSMYGJDRX-UHFFFAOYSA-N 0.000 claims 1
- PNBMCFSJJPCLTP-UHFFFAOYSA-N 3-amino-n-(4-methylphenyl)-5-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound C1=CC(C)=CC=C1NC(=O)N1C(NC=2C=CC(OCCN3CCCCC3)=CC=2)=NC(N)=N1 PNBMCFSJJPCLTP-UHFFFAOYSA-N 0.000 claims 1
- NBXVLSOIHGPLCB-UHFFFAOYSA-N 3-amino-n-cyclohexyl-5-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound C1CCCCC1NC(=O)N1N=C(N)N=C1NC(C=C1)=CC=C1OCCN1CCCCC1 NBXVLSOIHGPLCB-UHFFFAOYSA-N 0.000 claims 1
- YPQKZFJFBDPWCW-UHFFFAOYSA-N 3-amino-n-cyclopentyl-5-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound C1CCCC1NC(=O)N1N=C(N)N=C1NC(C=C1)=CC=C1OCCN1CCCCC1 YPQKZFJFBDPWCW-UHFFFAOYSA-N 0.000 claims 1
- IQSMMJOQMRCYDT-UHFFFAOYSA-N 4-[5-amino-3-(4-morpholin-4-ylanilino)-1,2,4-triazole-1-carbonyl]benzenesulfonamide Chemical compound N=1N(C(=O)C=2C=CC(=CC=2)S(N)(=O)=O)C(N)=NC=1NC(C=C1)=CC=C1N1CCOCC1 IQSMMJOQMRCYDT-UHFFFAOYSA-N 0.000 claims 1
- QUSPJWAWDJCOCQ-UHFFFAOYSA-N 5-amino-3-[4-(2-piperidin-1-ylethoxy)anilino]-n-(4-propan-2-ylphenyl)-1,2,4-triazole-1-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCCC3)=CC=2)=N1 QUSPJWAWDJCOCQ-UHFFFAOYSA-N 0.000 claims 1
- BTOYEEBQOWRPRR-UHFFFAOYSA-N 5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-n-(2,4,6-trifluorophenyl)-1,2,4-triazole-1-carbothioamide Chemical compound N=1N(C(=S)NC=2C(=CC(F)=CC=2F)F)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 BTOYEEBQOWRPRR-UHFFFAOYSA-N 0.000 claims 1
- NIGJHYOSJINNKT-UHFFFAOYSA-N 5-amino-n-(1,3-benzodioxol-5-yl)-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound N=1N(C(=O)NC=2C=C3OCOC3=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCCC1 NIGJHYOSJINNKT-UHFFFAOYSA-N 0.000 claims 1
- OCJLUGBCXCZFLO-UHFFFAOYSA-N 5-amino-n-(1,3-benzodioxol-5-yl)-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound N=1N(C(=O)NC=2C=C3OCOC3=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 OCJLUGBCXCZFLO-UHFFFAOYSA-N 0.000 claims 1
- JIWSSFJGSGHESS-UHFFFAOYSA-N 5-amino-n-(3-methoxyphenyl)-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound COC1=CC=CC(NC(=O)N2C(=NC(NC=3C=CC(OCCN4CCCCC4)=CC=3)=N2)N)=C1 JIWSSFJGSGHESS-UHFFFAOYSA-N 0.000 claims 1
- CGSXLCRJRJCZQF-UHFFFAOYSA-N 5-amino-n-(3-methoxyphenyl)-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound COC1=CC=CC(NC(=O)N2C(=NC(NC=3C=CC(OCCN4CCCC4)=CC=3)=N2)N)=C1 CGSXLCRJRJCZQF-UHFFFAOYSA-N 0.000 claims 1
- FETOGIDRJAFSQY-UHFFFAOYSA-N 5-amino-n-(3-methylphenyl)-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound CC1=CC=CC(NC(=O)N2C(=NC(NC=3C=CC(OCCN4CCCCC4)=CC=3)=N2)N)=C1 FETOGIDRJAFSQY-UHFFFAOYSA-N 0.000 claims 1
- VYFBEISNIGMDGI-UHFFFAOYSA-N 5-amino-n-(3-methylphenyl)-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound CC1=CC=CC(NC(=O)N2C(=NC(NC=3C=CC(OCCN4CCCC4)=CC=3)=N2)N)=C1 VYFBEISNIGMDGI-UHFFFAOYSA-N 0.000 claims 1
- PTRXCAWWXXDVNF-UHFFFAOYSA-N 5-amino-n-(4-butoxyphenyl)-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound C1=CC(OCCCC)=CC=C1NC(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCCC3)=CC=2)=N1 PTRXCAWWXXDVNF-UHFFFAOYSA-N 0.000 claims 1
- CWVPBBILDVOUCB-UHFFFAOYSA-N 5-amino-n-(4-chlorophenyl)-3-(4-methoxyanilino)-1,2,4-triazole-1-carboxamide Chemical compound C1=CC(OC)=CC=C1NC1=NN(C(=O)NC=2C=CC(Cl)=CC=2)C(N)=N1 CWVPBBILDVOUCB-UHFFFAOYSA-N 0.000 claims 1
- VIHVYWMMMNIANY-UHFFFAOYSA-N 5-amino-n-(4-cyanophenyl)-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound N=1N(C(=O)NC=2C=CC(=CC=2)C#N)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCCC1 VIHVYWMMMNIANY-UHFFFAOYSA-N 0.000 claims 1
- MEUIOPYIZCSGQF-UHFFFAOYSA-N 5-amino-n-(4-methoxyphenyl)-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCCC3)=CC=2)=N1 MEUIOPYIZCSGQF-UHFFFAOYSA-N 0.000 claims 1
- MMSDOUWVYRMHLJ-UHFFFAOYSA-N 5-amino-n-(4-methylphenyl)-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound C1=CC(C)=CC=C1NC(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCCC3)=CC=2)=N1 MMSDOUWVYRMHLJ-UHFFFAOYSA-N 0.000 claims 1
- UGVPDLRHCWVEJW-UHFFFAOYSA-N 5-amino-n-(4-methylphenyl)-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound C1=CC(C)=CC=C1NC(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCC3)=CC=2)=N1 UGVPDLRHCWVEJW-UHFFFAOYSA-N 0.000 claims 1
- QYCOLLKOCUDRML-UHFFFAOYSA-N 5-amino-n-[4-(dimethylamino)phenyl]-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound C1=CC(N(C)C)=CC=C1NC(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCCC3)=CC=2)=N1 QYCOLLKOCUDRML-UHFFFAOYSA-N 0.000 claims 1
- MLJXZBSCALPVLI-UHFFFAOYSA-N 5-amino-n-cyclohexyl-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound N=1N(C(=O)NC2CCCCC2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCCC1 MLJXZBSCALPVLI-UHFFFAOYSA-N 0.000 claims 1
- PORXTZDLWYFDLW-UHFFFAOYSA-N 5-amino-n-cyclopentyl-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carboxamide Chemical compound N=1N(C(=O)NC2CCCC2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCCC1 PORXTZDLWYFDLW-UHFFFAOYSA-N 0.000 claims 1
- OVRQYZBJLHHTOZ-UHFFFAOYSA-N 6-[5-amino-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carbonyl]-2,2-dimethyl-4h-1,4-benzoxazin-3-one Chemical compound C1=C2NC(=O)C(C)(C)OC2=CC=C1C(=O)N(C(=N1)N)N=C1NC(C=C1)=CC=C1OCCN1CCCCC1 OVRQYZBJLHHTOZ-UHFFFAOYSA-N 0.000 claims 1
- QHHRFPWWUKSBKP-UHFFFAOYSA-N 6-[5-amino-3-[4-[2-(dimethylamino)ethoxy]anilino]-1,2,4-triazole-1-carbonyl]-2,2-dimethyl-4h-1,4-benzoxazin-3-one Chemical compound C1=CC(OCCN(C)C)=CC=C1NC1=NN(C(=O)C=2C=C3NC(=O)C(C)(C)OC3=CC=2)C(N)=N1 QHHRFPWWUKSBKP-UHFFFAOYSA-N 0.000 claims 1
- UJVKQVLKMIBWAH-UHFFFAOYSA-N 6-[5-amino-3-[4-[2-(dimethylamino)propoxy]anilino]-1,2,4-triazole-1-carbonyl]-2,2-dimethyl-4h-1,4-benzoxazin-3-one Chemical compound C1=CC(OCC(C)N(C)C)=CC=C1NC1=NN(C(=O)C=2C=C3NC(=O)C(C)(C)OC3=CC=2)C(N)=N1 UJVKQVLKMIBWAH-UHFFFAOYSA-N 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- LHOUTXAZCFTRGH-UHFFFAOYSA-N [2,3-diamino-5-[3-[4-(2-chloro-6-fluorophenyl)piperazin-1-yl]propyl]-3h-1,2,4-triazol-1-yl]-(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)N2C(=NC(N)N2N)CCCN2CCN(CC2)C=2C(=CC=CC=2F)Cl)=C1 LHOUTXAZCFTRGH-UHFFFAOYSA-N 0.000 claims 1
- CQOUVRUJIPXIEZ-UHFFFAOYSA-N [2,5-diamino-3-(1,3-benzothiazol-2-yl)-3H-1,2,4-triazol-1-yl]-(3-methylphenyl)methanone Chemical compound NC1=NC(N(N1C(=O)C1=CC(=CC=C1)C)N)C=1SC2=C(N=1)C=CC=C2 CQOUVRUJIPXIEZ-UHFFFAOYSA-N 0.000 claims 1
- URKOBTDLSZYYOP-UHFFFAOYSA-N [2,5-diamino-3-(1,3-benzothiazol-6-yl)-3H-1,2,4-triazol-1-yl]-(3-methylphenyl)methanone Chemical compound NC1=NC(N(N1C(=O)C1=CC(=CC=C1)C)N)C1=CC2=C(N=CS2)C=C1 URKOBTDLSZYYOP-UHFFFAOYSA-N 0.000 claims 1
- YBWFKUVYTRUFIJ-UHFFFAOYSA-N [2,5-diamino-3-(1-benzofuran-5-yl)-3H-1,2,4-triazol-1-yl]-(3-methylphenyl)methanone Chemical compound NC1=NC(N(N1C(=O)C1=CC(=CC=C1)C)N)C=1C=CC2=C(C=CO2)C=1 YBWFKUVYTRUFIJ-UHFFFAOYSA-N 0.000 claims 1
- DEQPSUYLJXDODD-UHFFFAOYSA-N [2,5-diamino-3-(1-methylsulfonylpiperidin-4-yl)-3h-1,2,4-triazol-1-yl]-(2,6-difluorophenyl)methanone Chemical compound C1CN(S(=O)(=O)C)CCC1C1N(N)N(C(=O)C=2C(=CC=CC=2F)F)C(N)=N1 DEQPSUYLJXDODD-UHFFFAOYSA-N 0.000 claims 1
- FUAOVWRLKMLUTP-UHFFFAOYSA-N [2,5-diamino-3-(1-methylsulfonylpiperidin-4-yl)-3h-1,2,4-triazol-1-yl]-(4-morpholin-4-ylphenyl)methanone Chemical compound C1CN(S(=O)(=O)C)CCC1C1N(N)N(C(=O)C=2C=CC(=CC=2)N2CCOCC2)C(N)=N1 FUAOVWRLKMLUTP-UHFFFAOYSA-N 0.000 claims 1
- MWMNIKBCPLJPIN-UHFFFAOYSA-N [2,5-diamino-3-(1-methylsulfonylpiperidin-4-yl)-3h-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(C2CCN(CC2)S(C)(=O)=O)N1N MWMNIKBCPLJPIN-UHFFFAOYSA-N 0.000 claims 1
- XYIABQLOZPMVGT-UHFFFAOYSA-N [2,5-diamino-3-(1-methylsulfonylpiperidin-4-yl)-3h-1,2,4-triazol-1-yl]-[4-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound C1=CC(OC(C)(C)C)=CC=C1C(=O)N1C(N)=NC(C2CCN(CC2)S(C)(=O)=O)N1N XYIABQLOZPMVGT-UHFFFAOYSA-N 0.000 claims 1
- XMFZDWKBRWTQLW-UHFFFAOYSA-N [2,5-diamino-3-(1H-indazol-5-yl)-3H-1,2,4-triazol-1-yl]-(3-methylphenyl)methanone Chemical compound NC1=NC(N(N1C(=O)C1=CC(=CC=C1)C)N)C=1C=C2C=NNC2=CC=1 XMFZDWKBRWTQLW-UHFFFAOYSA-N 0.000 claims 1
- SSIHETFPKVFYTK-UHFFFAOYSA-N [2,5-diamino-3-(1H-indazol-6-yl)-3H-1,2,4-triazol-1-yl]-(3-methylphenyl)methanone Chemical compound NC1=NC(N(N1C(=O)C1=CC(=CC=C1)C)N)C1=CC=C2C=NNC2=C1 SSIHETFPKVFYTK-UHFFFAOYSA-N 0.000 claims 1
- SAWYAVDLNYURHI-UHFFFAOYSA-N [2,5-diamino-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-3H-1,2,4-triazol-1-yl]-(3,4-dimethylphenyl)methanone Chemical compound NC1=NC(N(N1C(=O)C1=CC(=C(C=C1)C)C)N)C1=CC2=C(OCCO2)C=C1 SAWYAVDLNYURHI-UHFFFAOYSA-N 0.000 claims 1
- WUMLFCZJZXBPBL-UHFFFAOYSA-N [2,5-diamino-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-3H-1,2,4-triazol-1-yl]-(3-ethoxyphenyl)methanone Chemical compound NC1=NC(N(N1C(=O)C1=CC(=CC=C1)OCC)N)C1=CC2=C(OCCO2)C=C1 WUMLFCZJZXBPBL-UHFFFAOYSA-N 0.000 claims 1
- NBEVFTZMUZNICA-UHFFFAOYSA-N [2,5-diamino-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-3h-1,2,4-triazol-1-yl]-(3-hydroxyphenyl)methanone Chemical compound NN1C(C=2C=C3OCCOC3=CC=2)N=C(N)N1C(=O)C1=CC=CC(O)=C1 NBEVFTZMUZNICA-UHFFFAOYSA-N 0.000 claims 1
- QJVSUXGQKZYQGM-UHFFFAOYSA-N [2,5-diamino-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-3h-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(C=2C=C3OCCOC3=CC=2)N1N QJVSUXGQKZYQGM-UHFFFAOYSA-N 0.000 claims 1
- XRELMNGFVBNAPA-UHFFFAOYSA-N [2,5-diamino-3-(2-methylindazol-5-yl)-3h-1,2,4-triazol-1-yl]-(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)N2C(=NC(N2N)C2=CC3=CN(C)N=C3C=C2)N)=C1 XRELMNGFVBNAPA-UHFFFAOYSA-N 0.000 claims 1
- HRZIILRJQYONQH-UHFFFAOYSA-N [2,5-diamino-3-[2-(methylaminomethyl)-1-benzofuran-5-yl]-3h-1,2,4-triazol-1-yl]-(3-methylphenyl)methanone Chemical compound C=1C=C2OC(CNC)=CC2=CC=1C(N1N)N=C(N)N1C(=O)C1=CC=CC(C)=C1 HRZIILRJQYONQH-UHFFFAOYSA-N 0.000 claims 1
- BALMEHDCBFUISW-UHFFFAOYSA-N [2,5-diamino-3-[3-fluoro-4-(2-pyrrolidin-1-ylethoxy)phenyl]-3H-1,2,4-triazol-1-yl]-(4-morpholin-4-ylphenyl)methanone Chemical compound NC1=NC(N(N1C(=O)C1=CC=C(C=C1)N1CCOCC1)N)C1=CC(=C(C=C1)OCCN1CCCC1)F BALMEHDCBFUISW-UHFFFAOYSA-N 0.000 claims 1
- KJUDSXRBQYZOHP-UHFFFAOYSA-N [3-amino-5-(4-morpholin-4-ylanilino)-1,2,4-triazol-1-yl]-(3-chlorophenyl)methanone Chemical compound C=1C=CC(Cl)=CC=1C(=O)N1N=C(N)N=C1NC(C=C1)=CC=C1N1CCOCC1 KJUDSXRBQYZOHP-UHFFFAOYSA-N 0.000 claims 1
- YAMHTOIRBNHPRV-UHFFFAOYSA-N [3-amino-5-(4-morpholin-4-ylanilino)-1,2,4-triazol-1-yl]-[4-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound C1=CC(OC(C)(C)C)=CC=C1C(=O)N1C(NC=2C=CC(=CC=2)N2CCOCC2)=NC(N)=N1 YAMHTOIRBNHPRV-UHFFFAOYSA-N 0.000 claims 1
- GSACMOLWQWNHHC-UHFFFAOYSA-N [3-amino-5-(4-piperidin-1-ylanilino)-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(NC=2C=CC(=CC=2)N2CCCCC2)=NC(N)=N1 GSACMOLWQWNHHC-UHFFFAOYSA-N 0.000 claims 1
- ARWILRUPFKEXIH-UHFFFAOYSA-N [3-amino-5-(4-propan-2-yloxyanilino)-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1NC1=NC(N)=NN1C(=O)C1=CC=C(C)C=C1 ARWILRUPFKEXIH-UHFFFAOYSA-N 0.000 claims 1
- IGGDGWHKKRPYTG-UHFFFAOYSA-N [3-amino-5-(4-pyrrolidin-1-ylanilino)-1,2,4-triazol-1-yl]-(4-tert-butylphenyl)methanone Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)N1C(NC=2C=CC(=CC=2)N2CCCC2)=NC(N)=N1 IGGDGWHKKRPYTG-UHFFFAOYSA-N 0.000 claims 1
- YWUDFDCAHCLFLP-UHFFFAOYSA-N [3-amino-5-[3-fluoro-4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-morpholin-4-ylphenyl)methanone Chemical compound C=1C=C(N2CCOCC2)C=CC=1C(=O)N1N=C(N)N=C1NC(C=C1F)=CC=C1OCCN1CCCC1 YWUDFDCAHCLFLP-UHFFFAOYSA-N 0.000 claims 1
- KACSJMQYPBBPAD-UHFFFAOYSA-N [3-amino-5-[4-(2-imidazol-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(1-benzothiophen-5-yl)methanone Chemical compound C=1C=C2SC=CC2=CC=1C(=O)N1N=C(N)N=C1NC(C=C1)=CC=C1OCCN1C=CN=C1 KACSJMQYPBBPAD-UHFFFAOYSA-N 0.000 claims 1
- GOGVMCNWFRNLKH-UHFFFAOYSA-N [3-amino-5-[4-(2-imidazol-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(1h-indol-6-yl)methanone Chemical compound C=1C=C2C=CNC2=CC=1C(=O)N1N=C(N)N=C1NC(C=C1)=CC=C1OCCN1C=CN=C1 GOGVMCNWFRNLKH-UHFFFAOYSA-N 0.000 claims 1
- GDOCQJQECKTDQF-UHFFFAOYSA-N [3-amino-5-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(NC=2C=CC(OCCN3CCCCC3)=CC=2)=NC(N)=N1 GDOCQJQECKTDQF-UHFFFAOYSA-N 0.000 claims 1
- HSYMYBLAGUXLNV-UHFFFAOYSA-N [3-amino-5-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(1-benzothiophen-2-yl)methanone Chemical compound C=1C2=CC=CC=C2SC=1C(=O)N1N=C(N)N=C1NC(C=C1)=CC=C1OCCN1CCCC1 HSYMYBLAGUXLNV-UHFFFAOYSA-N 0.000 claims 1
- HJZCNLFCOYPRAM-UHFFFAOYSA-N [3-amino-5-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(1h-indol-5-yl)methanone Chemical compound C=1C=C2NC=CC2=CC=1C(=O)N1N=C(N)N=C1NC(C=C1)=CC=C1OCCN1CCCC1 HJZCNLFCOYPRAM-UHFFFAOYSA-N 0.000 claims 1
- MNVTWSZOIHDXSQ-UHFFFAOYSA-N [3-amino-5-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(NC=2C=CC(OCCN3CCCC3)=CC=2)=NC(N)=N1 MNVTWSZOIHDXSQ-UHFFFAOYSA-N 0.000 claims 1
- SQVXTPGSUBDZOI-UHFFFAOYSA-N [3-amino-5-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-tert-butylphenyl)methanone Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)N1C(NC=2C=CC(OCCN3CCCC3)=CC=2)=NC(N)=N1 SQVXTPGSUBDZOI-UHFFFAOYSA-N 0.000 claims 1
- DOPLDBXCAMNGSL-KRWDZBQOSA-N [3-amino-5-[4-[2-[(3s)-3-fluoropyrrolidin-1-yl]ethoxy]anilino]-1,2,4-triazol-1-yl]-(1h-indol-6-yl)methanone Chemical compound C=1C=C2C=CNC2=CC=1C(=O)N1N=C(N)N=C1NC(C=C1)=CC=C1OCCN1CC[C@H](F)C1 DOPLDBXCAMNGSL-KRWDZBQOSA-N 0.000 claims 1
- FHABOEPEJLGKFW-INIZCTEOSA-N [3-amino-5-[4-[2-[(3s)-3-fluoropyrrolidin-1-yl]ethoxy]anilino]-1,2,4-triazol-1-yl]-(2,3-dihydro-1,4-benzodioxin-6-yl)methanone Chemical compound C=1C=C2OCCOC2=CC=1C(=O)N1N=C(N)N=C1NC(C=C1)=CC=C1OCCN1CC[C@H](F)C1 FHABOEPEJLGKFW-INIZCTEOSA-N 0.000 claims 1
- ZOXXNISZCDJSHC-UHFFFAOYSA-N [5-amino-2-(methylamino)-3-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-3h-1,2,4-triazol-1-yl]-[4-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound CNN1C(C=2C=CC(OCCN3CCCC3)=CC=2)N=C(N)N1C(=O)C1=CC=C(OC(C)(C)C)C=C1 ZOXXNISZCDJSHC-UHFFFAOYSA-N 0.000 claims 1
- OQPIXYBUHNAERJ-UHFFFAOYSA-N [5-amino-3-(2-fluoroanilino)-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C(N)=NC(NC=2C(=CC=CC=2)F)=N1 OQPIXYBUHNAERJ-UHFFFAOYSA-N 0.000 claims 1
- BFUDPBXLPDVIHJ-UHFFFAOYSA-N [5-amino-3-(2-hydroxyanilino)-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C(N)=NC(NC=2C(=CC=CC=2)O)=N1 BFUDPBXLPDVIHJ-UHFFFAOYSA-N 0.000 claims 1
- NUGLQFHGROHIHK-UHFFFAOYSA-N [5-amino-3-(2-methoxyanilino)-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound COC1=CC=CC=C1NC1=NN(C(=O)C=2C=CC(C)=CC=2)C(N)=N1 NUGLQFHGROHIHK-UHFFFAOYSA-N 0.000 claims 1
- PAVZHTWJNDMVJR-UHFFFAOYSA-N [5-amino-3-(2-methylanilino)-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C(N)=NC(NC=2C(=CC=CC=2)C)=N1 PAVZHTWJNDMVJR-UHFFFAOYSA-N 0.000 claims 1
- ZTMDOCGXWCVKFJ-UHFFFAOYSA-N [5-amino-3-(3,4-dihydro-2h-1,4-benzoxazin-6-ylamino)-1,2,4-triazol-1-yl]-(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)N2C(=NC(NC=3C=C4NCCOC4=CC=3)=N2)N)=C1 ZTMDOCGXWCVKFJ-UHFFFAOYSA-N 0.000 claims 1
- YROSLKRJRJJCGJ-UHFFFAOYSA-N [5-amino-3-(3-cyclopentyloxyanilino)-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=C(OC3CCCC3)C=CC=2)=N1 YROSLKRJRJJCGJ-UHFFFAOYSA-N 0.000 claims 1
- RVTCPELFVGUGTQ-UHFFFAOYSA-N [5-amino-3-(3-ethoxyanilino)-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound CCOC1=CC=CC(NC2=NN(C(N)=N2)C(=O)C=2C=CC(OC(C)C)=CC=2)=C1 RVTCPELFVGUGTQ-UHFFFAOYSA-N 0.000 claims 1
- OEKSEYFYLJZANB-UHFFFAOYSA-N [5-amino-3-(3-fluoroanilino)-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C(N)=NC(NC=2C=C(F)C=CC=2)=N1 OEKSEYFYLJZANB-UHFFFAOYSA-N 0.000 claims 1
- XWQXAZWAOANAOL-UHFFFAOYSA-N [5-amino-3-(3-hydroxyanilino)-1,2,4-triazol-1-yl]-(2-methylphenyl)methanone Chemical compound CC1=CC=CC=C1C(=O)N1C(N)=NC(NC=2C=C(O)C=CC=2)=N1 XWQXAZWAOANAOL-UHFFFAOYSA-N 0.000 claims 1
- SBAMECVUBCXTJJ-UHFFFAOYSA-N [5-amino-3-(3-hydroxyanilino)-1,2,4-triazol-1-yl]-(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)N2C(=NC(NC=3C=C(O)C=CC=3)=N2)N)=C1 SBAMECVUBCXTJJ-UHFFFAOYSA-N 0.000 claims 1
- NIEWTZVVVCBHRP-UHFFFAOYSA-N [5-amino-3-(3-hydroxyanilino)-1,2,4-triazol-1-yl]-(3-propan-2-yloxyphenyl)methanone Chemical compound CC(C)OC1=CC=CC(C(=O)N2C(=NC(NC=3C=C(O)C=CC=3)=N2)N)=C1 NIEWTZVVVCBHRP-UHFFFAOYSA-N 0.000 claims 1
- ZSPOTARGUFXWEP-UHFFFAOYSA-N [5-amino-3-(3-hydroxyanilino)-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C(N)=NC(NC=2C=C(O)C=CC=2)=N1 ZSPOTARGUFXWEP-UHFFFAOYSA-N 0.000 claims 1
- NTOSOZWMONIQTO-UHFFFAOYSA-N [5-amino-3-(3-methoxyanilino)-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound COC1=CC=CC(NC2=NN(C(N)=N2)C(=O)C=2C=CC(C)=CC=2)=C1 NTOSOZWMONIQTO-UHFFFAOYSA-N 0.000 claims 1
- JTWWSMPKROFXHG-UHFFFAOYSA-N [5-amino-3-(3-methoxyanilino)-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound COC1=CC=CC(NC2=NN(C(N)=N2)C(=O)C=2C=CC(OC(C)C)=CC=2)=C1 JTWWSMPKROFXHG-UHFFFAOYSA-N 0.000 claims 1
- XSDWBHUBORHKIM-UHFFFAOYSA-N [5-amino-3-(3-methylanilino)-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C(N)=NC(NC=2C=C(C)C=CC=2)=N1 XSDWBHUBORHKIM-UHFFFAOYSA-N 0.000 claims 1
- XXYFMLFSXBQDAL-UHFFFAOYSA-N [5-amino-3-(3-phenylmethoxyanilino)-1,2,4-triazol-1-yl]-(3-propan-2-yloxyphenyl)methanone Chemical compound CC(C)OC1=CC=CC(C(=O)N2C(=NC(NC=3C=C(OCC=4C=CC=CC=4)C=CC=3)=N2)N)=C1 XXYFMLFSXBQDAL-UHFFFAOYSA-N 0.000 claims 1
- IEADOYIUQKTHAN-UHFFFAOYSA-N [5-amino-3-(3-phenylmethoxyanilino)-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C(N)=NC(NC=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 IEADOYIUQKTHAN-UHFFFAOYSA-N 0.000 claims 1
- CTVFPODABLHDFW-UHFFFAOYSA-N [5-amino-3-(3-phenylmethoxyanilino)-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 CTVFPODABLHDFW-UHFFFAOYSA-N 0.000 claims 1
- ZCKMXMWHQPYTFB-UHFFFAOYSA-N [5-amino-3-(3-piperidin-1-ylanilino)-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=C(C=CC=2)N2CCCCC2)=N1 ZCKMXMWHQPYTFB-UHFFFAOYSA-N 0.000 claims 1
- KVHNGXZTVYSMKG-UHFFFAOYSA-N [5-amino-3-(3-propan-2-yloxyanilino)-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=C(OC(C)C)C=CC=2)=N1 KVHNGXZTVYSMKG-UHFFFAOYSA-N 0.000 claims 1
- CRWTXAWSTOUBPY-UHFFFAOYSA-N [5-amino-3-(4-cyclopentyloxyanilino)-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OC3CCCC3)=CC=2)=N1 CRWTXAWSTOUBPY-UHFFFAOYSA-N 0.000 claims 1
- KTWKCWXRONAAME-UHFFFAOYSA-N [5-amino-3-(4-ethoxyanilino)-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OCC)=CC=C1NC1=NN(C(=O)C=2C=CC(OC(C)C)=CC=2)C(N)=N1 KTWKCWXRONAAME-UHFFFAOYSA-N 0.000 claims 1
- AFQXHTAGFYVRPW-UHFFFAOYSA-N [5-amino-3-(4-fluoroanilino)-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(F)=CC=2)=N1 AFQXHTAGFYVRPW-UHFFFAOYSA-N 0.000 claims 1
- OVIUCSJCXKKNJJ-UHFFFAOYSA-N [5-amino-3-(4-hydroxyanilino)-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(O)=CC=2)=N1 OVIUCSJCXKKNJJ-UHFFFAOYSA-N 0.000 claims 1
- ROMZHUACZANVAS-UHFFFAOYSA-N [5-amino-3-(4-hydroxyanilino)-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(O)=CC=2)=N1 ROMZHUACZANVAS-UHFFFAOYSA-N 0.000 claims 1
- PGRFZXCATCWPFQ-UHFFFAOYSA-N [5-amino-3-(4-methoxyanilino)-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(OC)=CC=C1NC1=NN(C(=O)C=2C=CC(C)=CC=2)C(N)=N1 PGRFZXCATCWPFQ-UHFFFAOYSA-N 0.000 claims 1
- JWOMSOYDNCERMM-UHFFFAOYSA-N [5-amino-3-(4-methoxyanilino)-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1NC1=NN(C(=O)C=2C=CC(OC(C)C)=CC=2)C(N)=N1 JWOMSOYDNCERMM-UHFFFAOYSA-N 0.000 claims 1
- JXMJWYRRCBQRKQ-UHFFFAOYSA-N [5-amino-3-(4-methylanilino)-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1NC1=NN(C(=O)C=2C=CC(C)=CC=2)C(N)=N1 JXMJWYRRCBQRKQ-UHFFFAOYSA-N 0.000 claims 1
- WPDXVUKKZVHUMT-UHFFFAOYSA-N [5-amino-3-(4-morpholin-4-ylanilino)-1,2,4-triazol-1-yl]-(3-chlorophenyl)methanone Chemical compound N=1N(C(=O)C=2C=C(Cl)C=CC=2)C(N)=NC=1NC(C=C1)=CC=C1N1CCOCC1 WPDXVUKKZVHUMT-UHFFFAOYSA-N 0.000 claims 1
- GBIWMBFZQDGSRG-UHFFFAOYSA-N [5-amino-3-(4-morpholin-4-ylanilino)-1,2,4-triazol-1-yl]-(3-hydroxyphenyl)methanone Chemical compound N=1N(C(=O)C=2C=C(O)C=CC=2)C(N)=NC=1NC(C=C1)=CC=C1N1CCOCC1 GBIWMBFZQDGSRG-UHFFFAOYSA-N 0.000 claims 1
- XWFONUMJSAGLMV-UHFFFAOYSA-N [5-amino-3-(4-morpholin-4-ylanilino)-1,2,4-triazol-1-yl]-(3-methoxyphenyl)methanone Chemical compound COC1=CC=CC(C(=O)N2C(=NC(NC=3C=CC(=CC=3)N3CCOCC3)=N2)N)=C1 XWFONUMJSAGLMV-UHFFFAOYSA-N 0.000 claims 1
- KRHGGQWBCNCQHB-UHFFFAOYSA-N [5-amino-3-(4-morpholin-4-ylanilino)-1,2,4-triazol-1-yl]-(3-nitrophenyl)methanone Chemical compound N=1N(C(=O)C=2C=C(C=CC=2)[N+]([O-])=O)C(N)=NC=1NC(C=C1)=CC=C1N1CCOCC1 KRHGGQWBCNCQHB-UHFFFAOYSA-N 0.000 claims 1
- CACQLVPHSRQTNR-UHFFFAOYSA-N [5-amino-3-(4-morpholin-4-ylanilino)-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 CACQLVPHSRQTNR-UHFFFAOYSA-N 0.000 claims 1
- KHSASCQGHQWGFP-UHFFFAOYSA-N [5-amino-3-(4-morpholin-4-ylanilino)-1,2,4-triazol-1-yl]-[4-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound C1=CC(OC(C)(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 KHSASCQGHQWGFP-UHFFFAOYSA-N 0.000 claims 1
- CIHXFXPATZZNPJ-UHFFFAOYSA-N [5-amino-3-(4-phenylmethoxyanilino)-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCC=3C=CC=CC=3)=CC=2)=N1 CIHXFXPATZZNPJ-UHFFFAOYSA-N 0.000 claims 1
- JOSZMABFCXHDBH-UHFFFAOYSA-N [5-amino-3-(4-phenylmethoxyanilino)-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCC=3C=CC=CC=3)=CC=2)=N1 JOSZMABFCXHDBH-UHFFFAOYSA-N 0.000 claims 1
- GWIJZXSMIBPPJK-UHFFFAOYSA-N [5-amino-3-(4-piperidin-1-ylanilino)-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(=CC=2)N2CCCCC2)=N1 GWIJZXSMIBPPJK-UHFFFAOYSA-N 0.000 claims 1
- MSJGEBDRJWUUEM-UHFFFAOYSA-N [5-amino-3-(4-propan-2-yloxyanilino)-1,2,4-triazol-1-yl]-(3-chlorophenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1NC1=NN(C(=O)C=2C=C(Cl)C=CC=2)C(N)=N1 MSJGEBDRJWUUEM-UHFFFAOYSA-N 0.000 claims 1
- DEBRYXIHPKWISX-UHFFFAOYSA-N [5-amino-3-(4-propan-2-yloxyanilino)-1,2,4-triazol-1-yl]-(3-hydroxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1NC1=NN(C(=O)C=2C=C(O)C=CC=2)C(N)=N1 DEBRYXIHPKWISX-UHFFFAOYSA-N 0.000 claims 1
- AFMJPXURBDPFNN-UHFFFAOYSA-N [5-amino-3-(4-propan-2-yloxyanilino)-1,2,4-triazol-1-yl]-(3-nitrophenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1NC1=NN(C(=O)C=2C=C(C=CC=2)[N+]([O-])=O)C(N)=N1 AFMJPXURBDPFNN-UHFFFAOYSA-N 0.000 claims 1
- ZIMISXMLZKIXOO-UHFFFAOYSA-N [5-amino-3-(4-propan-2-yloxyanilino)-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1NC1=NN(C(=O)C=2C=CC(C)=CC=2)C(N)=N1 ZIMISXMLZKIXOO-UHFFFAOYSA-N 0.000 claims 1
- WUKWQNAOZUIDJV-UHFFFAOYSA-N [5-amino-3-(4-propan-2-yloxyanilino)-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1NC1=NN(C(=O)C=2C=CC(OC(C)C)=CC=2)C(N)=N1 WUKWQNAOZUIDJV-UHFFFAOYSA-N 0.000 claims 1
- USKQOUSSJZOGFN-UHFFFAOYSA-N [5-amino-3-(4-pyrrolidin-1-ylanilino)-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(=CC=2)N2CCCC2)=N1 USKQOUSSJZOGFN-UHFFFAOYSA-N 0.000 claims 1
- GWHUZSGTRWLXTN-UHFFFAOYSA-N [5-amino-3-(4-pyrrolidin-1-ylanilino)-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(=CC=2)N2CCCC2)=N1 GWHUZSGTRWLXTN-UHFFFAOYSA-N 0.000 claims 1
- DUUWJCNYIUQURS-UHFFFAOYSA-N [5-amino-3-(4-pyrrolidin-1-ylanilino)-1,2,4-triazol-1-yl]-(4-tert-butylphenyl)methanone Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(=CC=2)N2CCCC2)=N1 DUUWJCNYIUQURS-UHFFFAOYSA-N 0.000 claims 1
- ZAWSNEMNSCRYEH-UHFFFAOYSA-N [5-amino-3-(4-pyrrolidin-1-ylanilino)-1,2,4-triazol-1-yl]-[4-(dimethylamino)phenyl]methanone Chemical compound C1=CC(N(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(=CC=2)N2CCCC2)=N1 ZAWSNEMNSCRYEH-UHFFFAOYSA-N 0.000 claims 1
- GZLJNBYMXFJVIA-UHFFFAOYSA-N [5-amino-3-(4-pyrrolidin-1-ylanilino)-1,2,4-triazol-1-yl]-[4-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound C1=CC(OC(C)(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(=CC=2)N2CCCC2)=N1 GZLJNBYMXFJVIA-UHFFFAOYSA-N 0.000 claims 1
- WRUJVGCHPMKKBX-UHFFFAOYSA-N [5-amino-3-[3-(1,3-oxazol-5-yl)anilino]-1,2,4-triazol-1-yl]-(3-propan-2-yloxyphenyl)methanone Chemical compound CC(C)OC1=CC=CC(C(=O)N2C(=NC(NC=3C=C(C=CC=3)C=3OC=NC=3)=N2)N)=C1 WRUJVGCHPMKKBX-UHFFFAOYSA-N 0.000 claims 1
- XQGHEZHFRSCLGG-UHFFFAOYSA-N [5-amino-3-[3-(1,3-oxazol-5-yl)anilino]-1,2,4-triazol-1-yl]-(4-tert-butylphenyl)methanone Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=C(C=CC=2)C=2OC=NC=2)=N1 XQGHEZHFRSCLGG-UHFFFAOYSA-N 0.000 claims 1
- UNJVSZVPQZHWDD-UHFFFAOYSA-N [5-amino-3-[3-(1,3-oxazol-5-yl)anilino]-1,2,4-triazol-1-yl]-[4-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound C1=CC(OC(C)(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=C(C=CC=2)C=2OC=NC=2)=N1 UNJVSZVPQZHWDD-UHFFFAOYSA-N 0.000 claims 1
- MQWXEAYFRAPFDJ-UHFFFAOYSA-N [5-amino-3-[3-(2,2,2-trifluoroethoxy)anilino]-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=C(OCC(F)(F)F)C=CC=2)=N1 MQWXEAYFRAPFDJ-UHFFFAOYSA-N 0.000 claims 1
- KMCDDVSCAQHYFA-UHFFFAOYSA-N [5-amino-3-[3-(2-methoxyethoxymethoxy)anilino]-1,2,4-triazol-1-yl]-(3-methylphenyl)methanone Chemical compound COCCOCOC1=CC=CC(NC2=NN(C(N)=N2)C(=O)C=2C=C(C)C=CC=2)=C1 KMCDDVSCAQHYFA-UHFFFAOYSA-N 0.000 claims 1
- QPWSKUAWBAVQDT-UHFFFAOYSA-N [5-amino-3-[3-[2-(1,3-dioxolan-2-yl)ethoxy]anilino]-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=C(OCCC3OCCO3)C=CC=2)=N1 QPWSKUAWBAVQDT-UHFFFAOYSA-N 0.000 claims 1
- XITMXCIKKYYJKM-UHFFFAOYSA-N [5-amino-3-[3-chloro-4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(3,5-dichlorophenyl)methanone Chemical compound N=1N(C(=O)C=2C=C(Cl)C=C(Cl)C=2)C(N)=NC=1NC(C=C1Cl)=CC=C1OCCN1CCCC1 XITMXCIKKYYJKM-UHFFFAOYSA-N 0.000 claims 1
- GUUQUTINQDKMLJ-UHFFFAOYSA-N [5-amino-3-[3-fluoro-4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(1h-indol-6-yl)methanone Chemical compound N=1N(C(=O)C=2C=C3NC=CC3=CC=2)C(N)=NC=1NC(C=C1F)=CC=C1OCCN1CCCC1 GUUQUTINQDKMLJ-UHFFFAOYSA-N 0.000 claims 1
- OSGDJRWDQMDIDW-UHFFFAOYSA-N [5-amino-3-[3-fluoro-4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=C(F)C(OCCN3CCCC3)=CC=2)=N1 OSGDJRWDQMDIDW-UHFFFAOYSA-N 0.000 claims 1
- DQMITHQZJPBMCK-UHFFFAOYSA-N [5-amino-3-[3-fluoro-4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[4-(thiadiazol-4-yl)phenyl]methanone Chemical compound N=1N(C(=O)C=2C=CC(=CC=2)C=2N=NSC=2)C(N)=NC=1NC(C=C1F)=CC=C1OCCN1CCCC1 DQMITHQZJPBMCK-UHFFFAOYSA-N 0.000 claims 1
- WQNMUCAEKYIKPD-UHFFFAOYSA-N [5-amino-3-[3-fluoro-4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[4-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound C1=CC(OC(C)(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=C(F)C(OCCN3CCCC3)=CC=2)=N1 WQNMUCAEKYIKPD-UHFFFAOYSA-N 0.000 claims 1
- ZYMYIFUSNBYWMO-UHFFFAOYSA-N [5-amino-3-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(1h-indol-6-yl)methanone Chemical compound COC1=CC(NC2=NN(C(N)=N2)C(=O)C=2C=C3NC=CC3=CC=2)=CC=C1OCCN1CCCC1 ZYMYIFUSNBYWMO-UHFFFAOYSA-N 0.000 claims 1
- URMOUCIRWULZEC-UHFFFAOYSA-N [5-amino-3-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(3-morpholin-4-ylphenyl)methanone Chemical compound C=1C=C(OCCN2CCCC2)C(OC)=CC=1NC(=N1)N=C(N)N1C(=O)C(C=1)=CC=CC=1N1CCOCC1 URMOUCIRWULZEC-UHFFFAOYSA-N 0.000 claims 1
- CJQSCIOUAXMXTQ-UHFFFAOYSA-N [5-amino-3-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-morpholin-4-ylphenyl)methanone Chemical compound C=1C=C(OCCN2CCCC2)C(OC)=CC=1NC(=N1)N=C(N)N1C(=O)C(C=C1)=CC=C1N1CCOCC1 CJQSCIOUAXMXTQ-UHFFFAOYSA-N 0.000 claims 1
- ZDANCCLBWWQTLX-UHFFFAOYSA-N [5-amino-3-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C=1C=C(OCCN2CCCC2)C(OC)=CC=1NC(=N1)N=C(N)N1C(=O)C1=CC=C(OC(C)C)C=C1 ZDANCCLBWWQTLX-UHFFFAOYSA-N 0.000 claims 1
- UVEHFXQUYPPGSJ-UHFFFAOYSA-N [5-amino-3-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-tert-butylphenyl)methanone Chemical compound C=1C=C(OCCN2CCCC2)C(OC)=CC=1NC(=N1)N=C(N)N1C(=O)C1=CC=C(C(C)(C)C)C=C1 UVEHFXQUYPPGSJ-UHFFFAOYSA-N 0.000 claims 1
- UPNCSRBLWNDCLA-UHFFFAOYSA-N [5-amino-3-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[4-(thiadiazol-4-yl)phenyl]methanone Chemical compound C=1C=C(OCCN2CCCC2)C(OC)=CC=1NC(=N1)N=C(N)N1C(=O)C(C=C1)=CC=C1C1=CSN=N1 UPNCSRBLWNDCLA-UHFFFAOYSA-N 0.000 claims 1
- JMNJCGDJIZJZDI-UHFFFAOYSA-N [5-amino-3-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[4-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound C=1C=C(OCCN2CCCC2)C(OC)=CC=1NC(=N1)N=C(N)N1C(=O)C1=CC=C(OC(C)(C)C)C=C1 JMNJCGDJIZJZDI-UHFFFAOYSA-N 0.000 claims 1
- PISIQYPJOQFVTJ-UHFFFAOYSA-N [5-amino-3-[4-(2,2,2-trifluoroethoxy)anilino]-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCC(F)(F)F)=CC=2)=N1 PISIQYPJOQFVTJ-UHFFFAOYSA-N 0.000 claims 1
- BQUBZOLEDXRCRX-UHFFFAOYSA-N [5-amino-3-[4-(2-imidazol-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(1-benzothiophen-5-yl)methanone Chemical compound N=1N(C(=O)C=2C=C3C=CSC3=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1C=CN=C1 BQUBZOLEDXRCRX-UHFFFAOYSA-N 0.000 claims 1
- MHGGOJPSDKGXSZ-UHFFFAOYSA-N [5-amino-3-[4-(2-imidazol-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(1h-indol-6-yl)methanone Chemical compound N=1N(C(=O)C=2C=C3NC=CC3=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1C=CN=C1 MHGGOJPSDKGXSZ-UHFFFAOYSA-N 0.000 claims 1
- FEHRWSIQRQSCMY-UHFFFAOYSA-N [5-amino-3-[4-(2-imidazol-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3C=NC=C3)=CC=2)=N1 FEHRWSIQRQSCMY-UHFFFAOYSA-N 0.000 claims 1
- DOUNFQJIVHESII-UHFFFAOYSA-N [5-amino-3-[4-(2-imidazol-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[3-(dimethylamino)phenyl]methanone Chemical compound CN(C)C1=CC=CC(C(=O)N2C(=NC(NC=3C=CC(OCCN4C=NC=C4)=CC=3)=N2)N)=C1 DOUNFQJIVHESII-UHFFFAOYSA-N 0.000 claims 1
- RVDDPBMCAOCDTF-UHFFFAOYSA-N [5-amino-3-[4-(2-imidazol-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[3-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound CC(C)(C)OC1=CC=CC(C(=O)N2C(=NC(NC=3C=CC(OCCN4C=NC=C4)=CC=3)=N2)N)=C1 RVDDPBMCAOCDTF-UHFFFAOYSA-N 0.000 claims 1
- MYKPNNASKZETTG-UHFFFAOYSA-N [5-amino-3-[4-(2-imidazol-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[4-(dimethylamino)phenyl]methanone Chemical compound C1=CC(N(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3C=NC=C3)=CC=2)=N1 MYKPNNASKZETTG-UHFFFAOYSA-N 0.000 claims 1
- ZACGBOPBKWBMNQ-UHFFFAOYSA-N [5-amino-3-[4-(2-imidazol-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[4-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound C1=CC(OC(C)(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3C=NC=C3)=CC=2)=N1 ZACGBOPBKWBMNQ-UHFFFAOYSA-N 0.000 claims 1
- CCEDDBIKOFRKAH-UHFFFAOYSA-N [5-amino-3-[4-(2-morpholin-4-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(1h-indol-6-yl)methanone Chemical compound N=1N(C(=O)C=2C=C3NC=CC3=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCOCC1 CCEDDBIKOFRKAH-UHFFFAOYSA-N 0.000 claims 1
- LWSNIUDTSIXZLQ-UHFFFAOYSA-N [5-amino-3-[4-(2-morpholin-4-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(3-propan-2-yloxyphenyl)methanone Chemical compound CC(C)OC1=CC=CC(C(=O)N2C(=NC(NC=3C=CC(OCCN4CCOCC4)=CC=3)=N2)N)=C1 LWSNIUDTSIXZLQ-UHFFFAOYSA-N 0.000 claims 1
- BNCJZNFFMKONCE-UHFFFAOYSA-N [5-amino-3-[4-(2-morpholin-4-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-tert-butylphenyl)methanone Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCOCC3)=CC=2)=N1 BNCJZNFFMKONCE-UHFFFAOYSA-N 0.000 claims 1
- JPPJJTBLJIPAPV-UHFFFAOYSA-N [5-amino-3-[4-(2-morpholin-4-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(5-propan-2-yloxypyridin-3-yl)methanone Chemical compound CC(C)OC1=CN=CC(C(=O)N2C(=NC(NC=3C=CC(OCCN4CCOCC4)=CC=3)=N2)N)=C1 JPPJJTBLJIPAPV-UHFFFAOYSA-N 0.000 claims 1
- YSSWVNQEOOTDTP-UHFFFAOYSA-N [5-amino-3-[4-(2-morpholin-4-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[4-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound C1=CC(OC(C)(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCOCC3)=CC=2)=N1 YSSWVNQEOOTDTP-UHFFFAOYSA-N 0.000 claims 1
- BPEVRXXPXGUPDS-UHFFFAOYSA-N [5-amino-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(1,3-benzodioxol-5-yl)methanone Chemical compound N=1N(C(=O)C=2C=C3OCOC3=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCCC1 BPEVRXXPXGUPDS-UHFFFAOYSA-N 0.000 claims 1
- FDJDVHPUNMJXQS-UHFFFAOYSA-N [5-amino-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(3-methoxyphenyl)methanone Chemical compound COC1=CC=CC(C(=O)N2C(=NC(NC=3C=CC(OCCN4CCCCC4)=CC=3)=N2)N)=C1 FDJDVHPUNMJXQS-UHFFFAOYSA-N 0.000 claims 1
- NYITYFXTQCODBO-UHFFFAOYSA-N [5-amino-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)N2C(=NC(NC=3C=CC(OCCN4CCCCC4)=CC=3)=N2)N)=C1 NYITYFXTQCODBO-UHFFFAOYSA-N 0.000 claims 1
- BYZKVVOYVLHTOF-UHFFFAOYSA-N [5-amino-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(3-propan-2-yloxyphenyl)methanone Chemical compound CC(C)OC1=CC=CC(C(=O)N2C(=NC(NC=3C=CC(OCCN4CCCCC4)=CC=3)=N2)N)=C1 BYZKVVOYVLHTOF-UHFFFAOYSA-N 0.000 claims 1
- VWAKZHUAFAJYAX-UHFFFAOYSA-N [5-amino-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-cyclohexylphenyl)methanone Chemical compound N=1N(C(=O)C=2C=CC(=CC=2)C2CCCCC2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCCC1 VWAKZHUAFAJYAX-UHFFFAOYSA-N 0.000 claims 1
- XEVZDAFRTZGAGE-UHFFFAOYSA-N [5-amino-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-methoxycyclohexyl)methanone Chemical compound C1CC(OC)CCC1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCCC3)=CC=2)=N1 XEVZDAFRTZGAGE-UHFFFAOYSA-N 0.000 claims 1
- SNRIEVIEGREGBS-UHFFFAOYSA-N [5-amino-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCCC3)=CC=2)=N1 SNRIEVIEGREGBS-UHFFFAOYSA-N 0.000 claims 1
- BKLAEZKISLKCGC-UHFFFAOYSA-N [5-amino-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-propan-2-ylphenyl)methanone Chemical compound C1=CC(C(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCCC3)=CC=2)=N1 BKLAEZKISLKCGC-UHFFFAOYSA-N 0.000 claims 1
- YGWABRHGGYRWCP-UHFFFAOYSA-N [5-amino-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[3-(dimethylamino)phenyl]methanone Chemical compound CN(C)C1=CC=CC(C(=O)N2C(=NC(NC=3C=CC(OCCN4CCCCC4)=CC=3)=N2)N)=C1 YGWABRHGGYRWCP-UHFFFAOYSA-N 0.000 claims 1
- BOHVUNKJZMUFQG-UHFFFAOYSA-N [5-amino-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[4-(dimethylamino)phenyl]methanone Chemical compound C1=CC(N(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCCC3)=CC=2)=N1 BOHVUNKJZMUFQG-UHFFFAOYSA-N 0.000 claims 1
- FHGYTIPUBYTWLH-UHFFFAOYSA-N [5-amino-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[4-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound C1=CC(OC(C)(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCCC3)=CC=2)=N1 FHGYTIPUBYTWLH-UHFFFAOYSA-N 0.000 claims 1
- ZIQGXJRCUSDDSP-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(1,3-benzodioxol-5-yl)methanone Chemical compound N=1N(C(=O)C=2C=C3OCOC3=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 ZIQGXJRCUSDDSP-UHFFFAOYSA-N 0.000 claims 1
- NPOGYEKLJFATEZ-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(1,3-benzothiazol-6-yl)methanone Chemical compound N=1N(C(=O)C=2C=C3SC=NC3=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 NPOGYEKLJFATEZ-UHFFFAOYSA-N 0.000 claims 1
- IQVMMLHCIWFEMX-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(1-benzothiophen-2-yl)methanone Chemical compound N=1N(C(=O)C=2SC3=CC=CC=C3C=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 IQVMMLHCIWFEMX-UHFFFAOYSA-N 0.000 claims 1
- BMTGRPKVKCRHNL-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(1-benzothiophen-5-yl)methanone Chemical compound N=1N(C(=O)C=2C=C3C=CSC3=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 BMTGRPKVKCRHNL-UHFFFAOYSA-N 0.000 claims 1
- ONIFBTFCFMFNLG-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(1h-indol-2-yl)methanone Chemical compound N=1N(C(=O)C=2NC3=CC=CC=C3C=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 ONIFBTFCFMFNLG-UHFFFAOYSA-N 0.000 claims 1
- CSAVOUREYLKSFH-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(1h-indol-3-yl)methanone Chemical compound N=1N(C(=O)C=2C3=CC=CC=C3NC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 CSAVOUREYLKSFH-UHFFFAOYSA-N 0.000 claims 1
- IYTRLEVOIVCSKS-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(1h-indol-5-yl)methanone Chemical compound N=1N(C(=O)C=2C=C3C=CNC3=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 IYTRLEVOIVCSKS-UHFFFAOYSA-N 0.000 claims 1
- ZDODCAMEJADIMO-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(1h-indol-6-yl)methanone Chemical compound N=1N(C(=O)C=2C=C3NC=CC3=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 ZDODCAMEJADIMO-UHFFFAOYSA-N 0.000 claims 1
- WHUVIORJCJRDGQ-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(2,3-dihydro-1,4-benzodioxin-6-yl)methanone Chemical compound N=1N(C(=O)C=2C=C3OCCOC3=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 WHUVIORJCJRDGQ-UHFFFAOYSA-N 0.000 claims 1
- OFQZIFROVVDBOL-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(2,3-dihydro-1-benzofuran-5-yl)methanone Chemical compound N=1N(C(=O)C=2C=C3CCOC3=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 OFQZIFROVVDBOL-UHFFFAOYSA-N 0.000 claims 1
- PQKHESAPHRHJGE-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(2,6-difluorophenyl)methanone Chemical compound N=1N(C(=O)C=2C(=CC=CC=2F)F)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 PQKHESAPHRHJGE-UHFFFAOYSA-N 0.000 claims 1
- CORYDBAMRNVLSN-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(2h-benzotriazol-5-yl)methanone Chemical compound N=1N(C(=O)C=2C=C3N=NNC3=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 CORYDBAMRNVLSN-UHFFFAOYSA-N 0.000 claims 1
- JFPTZTHNFDZNSH-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(3,5-difluoro-4-methoxyphenyl)methanone Chemical compound C1=C(F)C(OC)=C(F)C=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCC3)=CC=2)=N1 JFPTZTHNFDZNSH-UHFFFAOYSA-N 0.000 claims 1
- JOMLJZGDYYOAHL-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(3-fluoro-4-methoxyphenyl)methanone Chemical compound C1=C(F)C(OC)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCC3)=CC=2)=N1 JOMLJZGDYYOAHL-UHFFFAOYSA-N 0.000 claims 1
- LPNNBSRAMLWSKI-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(3-methoxyphenyl)methanone Chemical compound COC1=CC=CC(C(=O)N2C(=NC(NC=3C=CC(OCCN4CCCC4)=CC=3)=N2)N)=C1 LPNNBSRAMLWSKI-UHFFFAOYSA-N 0.000 claims 1
- VGJBJKUKHFUGTO-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)N2C(=NC(NC=3C=CC(OCCN4CCCC4)=CC=3)=N2)N)=C1 VGJBJKUKHFUGTO-UHFFFAOYSA-N 0.000 claims 1
- YYEUAPZIXFZNMD-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(3-methylthiophen-2-yl)methanone Chemical compound C1=CSC(C(=O)N2C(=NC(NC=3C=CC(OCCN4CCCC4)=CC=3)=N2)N)=C1C YYEUAPZIXFZNMD-UHFFFAOYSA-N 0.000 claims 1
- FVBWHRIQXBWKJL-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(3-morpholin-4-ylphenyl)methanone Chemical compound N=1N(C(=O)C=2C=C(C=CC=2)N2CCOCC2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 FVBWHRIQXBWKJL-UHFFFAOYSA-N 0.000 claims 1
- PMJKSODWBZVCKQ-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(3-thiophen-2-ylphenyl)methanone Chemical compound N=1N(C(=O)C=2C=C(C=CC=2)C=2SC=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 PMJKSODWBZVCKQ-UHFFFAOYSA-N 0.000 claims 1
- XYCPGWBYOGDHGU-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(3h-benzimidazol-5-yl)methanone Chemical compound N=1N(C(=O)C=2C=C3N=CNC3=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 XYCPGWBYOGDHGU-UHFFFAOYSA-N 0.000 claims 1
- JRTMMKHRRJVMIA-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-imidazol-1-ylphenyl)methanone Chemical compound N=1N(C(=O)C=2C=CC(=CC=2)N2C=NC=C2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 JRTMMKHRRJVMIA-UHFFFAOYSA-N 0.000 claims 1
- YPDRFTHPKGCNKC-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCC3)=CC=2)=N1 YPDRFTHPKGCNKC-UHFFFAOYSA-N 0.000 claims 1
- XCNPORZRTBGECV-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-methylsulfanylphenyl)methanone Chemical compound C1=CC(SC)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCC3)=CC=2)=N1 XCNPORZRTBGECV-UHFFFAOYSA-N 0.000 claims 1
- VQBUVCCAVJNXTB-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-morpholin-4-ylphenyl)methanone Chemical compound N=1N(C(=O)C=2C=CC(=CC=2)N2CCOCC2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 VQBUVCCAVJNXTB-UHFFFAOYSA-N 0.000 claims 1
- WPWOVYCWRHJLFI-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-phenoxyphenyl)methanone Chemical compound N=1N(C(=O)C=2C=CC(OC=3C=CC=CC=3)=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 WPWOVYCWRHJLFI-UHFFFAOYSA-N 0.000 claims 1
- HNGQGDXHGHDVQQ-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-phenylphenyl)methanone Chemical compound N=1N(C(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 HNGQGDXHGHDVQQ-UHFFFAOYSA-N 0.000 claims 1
- PFUCBZSHERSSMK-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-piperidin-1-ylphenyl)methanone Chemical compound N=1N(C(=O)C=2C=CC(=CC=2)N2CCCCC2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 PFUCBZSHERSSMK-UHFFFAOYSA-N 0.000 claims 1
- NZFYFXXAFWORRR-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCC3)=CC=2)=N1 NZFYFXXAFWORRR-UHFFFAOYSA-N 0.000 claims 1
- ZWCJHARTEPCQKR-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-pyrrol-1-ylphenyl)methanone Chemical compound N=1N(C(=O)C=2C=CC(=CC=2)N2C=CC=C2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 ZWCJHARTEPCQKR-UHFFFAOYSA-N 0.000 claims 1
- VGWPIIJLYJCPRW-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-tert-butylphenyl)methanone Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCC3)=CC=2)=N1 VGWPIIJLYJCPRW-UHFFFAOYSA-N 0.000 claims 1
- JURGVAAAABAXNS-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-thiophen-2-ylphenyl)methanone Chemical compound N=1N(C(=O)C=2C=CC(=CC=2)C=2SC=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 JURGVAAAABAXNS-UHFFFAOYSA-N 0.000 claims 1
- MDOGREYYFSEAQG-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(4-thiophen-3-ylphenyl)methanone Chemical compound N=1N(C(=O)C=2C=CC(=CC=2)C2=CSC=C2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 MDOGREYYFSEAQG-UHFFFAOYSA-N 0.000 claims 1
- BKVPHHPGQXHQIG-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(5-methylthiophen-2-yl)methanone Chemical compound S1C(C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCC3)=CC=2)=N1 BKVPHHPGQXHQIG-UHFFFAOYSA-N 0.000 claims 1
- LYQSVOHKMQPJQX-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(6-methylpyridin-3-yl)methanone Chemical compound C1=NC(C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCC3)=CC=2)=N1 LYQSVOHKMQPJQX-UHFFFAOYSA-N 0.000 claims 1
- OABDRYPHXGUPKA-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-(thiadiazol-4-yl)methanone Chemical compound N=1N(C(=O)C=2N=NSC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 OABDRYPHXGUPKA-UHFFFAOYSA-N 0.000 claims 1
- NUQOBIBOZOZSKA-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[3-(1,3-thiazol-2-yl)phenyl]methanone Chemical compound N=1N(C(=O)C=2C=C(C=CC=2)C=2SC=CN=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 NUQOBIBOZOZSKA-UHFFFAOYSA-N 0.000 claims 1
- GGYFSOQVTYQKKI-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[3-(dimethylamino)phenyl]methanone Chemical compound CN(C)C1=CC=CC(C(=O)N2C(=NC(NC=3C=CC(OCCN4CCCC4)=CC=3)=N2)N)=C1 GGYFSOQVTYQKKI-UHFFFAOYSA-N 0.000 claims 1
- QKQFKLKHQPURLC-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[3-(trifluoromethoxy)phenyl]methanone Chemical compound N=1N(C(=O)C=2C=C(OC(F)(F)F)C=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 QKQFKLKHQPURLC-UHFFFAOYSA-N 0.000 claims 1
- WQABRBOHQKAGIX-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[3-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound CC(C)(C)OC1=CC=CC(C(=O)N2C(=NC(NC=3C=CC(OCCN4CCCC4)=CC=3)=N2)N)=C1 WQABRBOHQKAGIX-UHFFFAOYSA-N 0.000 claims 1
- PQUGTXSHVVNXGK-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[4-(1,1-dioxo-1,4-thiazinan-4-yl)phenyl]methanone Chemical compound N=1N(C(=O)C=2C=CC(=CC=2)N2CCS(=O)(=O)CC2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 PQUGTXSHVVNXGK-UHFFFAOYSA-N 0.000 claims 1
- FRJPNVYGGMNDKH-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[4-(2-morpholin-4-ylethoxy)phenyl]methanone Chemical compound N=1N(C(=O)C=2C=CC(OCCN3CCOCC3)=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 FRJPNVYGGMNDKH-UHFFFAOYSA-N 0.000 claims 1
- WWBHUVBMAAKYTD-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[4-(4-methylpiperazin-1-yl)phenyl]methanone Chemical compound C1CN(C)CCN1C1=CC=C(C(=O)N2C(=NC(NC=3C=CC(OCCN4CCCC4)=CC=3)=N2)N)C=C1 WWBHUVBMAAKYTD-UHFFFAOYSA-N 0.000 claims 1
- QLIJTNYNWQTFJL-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[4-(dimethylamino)phenyl]methanone Chemical compound C1=CC(N(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCC3)=CC=2)=N1 QLIJTNYNWQTFJL-UHFFFAOYSA-N 0.000 claims 1
- ULUOWDCBDMRKQY-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[4-(methylamino)phenyl]methanone Chemical compound C1=CC(NC)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCC3)=CC=2)=N1 ULUOWDCBDMRKQY-UHFFFAOYSA-N 0.000 claims 1
- QPNSYKAASHLMTD-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-[4-(trifluoromethoxy)phenyl]methanone Chemical compound N=1N(C(=O)C=2C=CC(OC(F)(F)F)=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 QPNSYKAASHLMTD-UHFFFAOYSA-N 0.000 claims 1
- VVXKZDOHRSPBKA-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-pyridin-2-ylmethanone Chemical compound N=1N(C(=O)C=2N=CC=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 VVXKZDOHRSPBKA-UHFFFAOYSA-N 0.000 claims 1
- UNTQWXDZVIBUMJ-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-pyridin-4-ylmethanone Chemical compound N=1N(C(=O)C=2C=CN=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 UNTQWXDZVIBUMJ-UHFFFAOYSA-N 0.000 claims 1
- PAIGVINSUPDERH-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-quinolin-6-ylmethanone Chemical compound N=1N(C(=O)C=2C=C3C=CC=NC3=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 PAIGVINSUPDERH-UHFFFAOYSA-N 0.000 claims 1
- YEDRNIKVSDLMJF-UHFFFAOYSA-N [5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazol-1-yl]-thiophen-2-ylmethanone Chemical compound N=1N(C(=O)C=2SC=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 YEDRNIKVSDLMJF-UHFFFAOYSA-N 0.000 claims 1
- UXLMZOQRVBYXOV-UHFFFAOYSA-N [5-amino-3-[4-(3-pyrrolidin-1-ylpropoxy)anilino]-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCCN3CCCC3)=CC=2)=N1 UXLMZOQRVBYXOV-UHFFFAOYSA-N 0.000 claims 1
- NVAQRBJFFXCQBG-UHFFFAOYSA-N [5-amino-3-[4-(3-pyrrolidin-1-ylpropoxy)anilino]-1,2,4-triazol-1-yl]-[3-(dimethylamino)phenyl]methanone Chemical compound CN(C)C1=CC=CC(C(=O)N2C(=NC(NC=3C=CC(OCCCN4CCCC4)=CC=3)=N2)N)=C1 NVAQRBJFFXCQBG-UHFFFAOYSA-N 0.000 claims 1
- ATVCXCKXBKWGAJ-UHFFFAOYSA-N [5-amino-3-[4-(3-pyrrolidin-1-ylpropoxy)anilino]-1,2,4-triazol-1-yl]-[3-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound CC(C)(C)OC1=CC=CC(C(=O)N2C(=NC(NC=3C=CC(OCCCN4CCCC4)=CC=3)=N2)N)=C1 ATVCXCKXBKWGAJ-UHFFFAOYSA-N 0.000 claims 1
- WWKVOBHYPQZZRF-UHFFFAOYSA-N [5-amino-3-[4-(3-pyrrolidin-1-ylpropoxy)anilino]-1,2,4-triazol-1-yl]-[4-(dimethylamino)phenyl]methanone Chemical compound C1=CC(N(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCCN3CCCC3)=CC=2)=N1 WWKVOBHYPQZZRF-UHFFFAOYSA-N 0.000 claims 1
- UWICBMGEYYSKFU-UHFFFAOYSA-N [5-amino-3-[4-(3-pyrrolidin-1-ylpropoxy)anilino]-1,2,4-triazol-1-yl]-[4-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound C1=CC(OC(C)(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCCN3CCCC3)=CC=2)=N1 UWICBMGEYYSKFU-UHFFFAOYSA-N 0.000 claims 1
- DENMOERQBFNUFG-UHFFFAOYSA-N [5-amino-3-[4-(4-methylpiperazin-1-yl)anilino]-1,2,4-triazol-1-yl]-(3-bicyclo[2.2.1]heptanyl)methanone Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NN(C(=O)C2C3CCC(C3)C2)C(N)=N1 DENMOERQBFNUFG-UHFFFAOYSA-N 0.000 claims 1
- BXNUTPVLNVOCMN-UHFFFAOYSA-N [5-amino-3-[4-(4-methylpiperazin-1-yl)anilino]-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(=CC=2)N2CCN(C)CC2)=N1 BXNUTPVLNVOCMN-UHFFFAOYSA-N 0.000 claims 1
- DIQOIGFWGSXDON-UHFFFAOYSA-N [5-amino-3-[4-(4-methylpiperazin-1-yl)anilino]-1,2,4-triazol-1-yl]-[3-(dimethylamino)phenyl]methanone Chemical compound CN(C)C1=CC=CC(C(=O)N2C(=NC(NC=3C=CC(=CC=3)N3CCN(C)CC3)=N2)N)=C1 DIQOIGFWGSXDON-UHFFFAOYSA-N 0.000 claims 1
- CXXLXGKNCWBXEF-UHFFFAOYSA-N [5-amino-3-[4-(4-methylpiperazin-1-yl)anilino]-1,2,4-triazol-1-yl]-[3-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NN(C(=O)C=2C=C(OC(C)(C)C)C=CC=2)C(N)=N1 CXXLXGKNCWBXEF-UHFFFAOYSA-N 0.000 claims 1
- FHOIHBNTAWYUMB-UHFFFAOYSA-N [5-amino-3-[4-(4-methylpiperazin-1-yl)anilino]-1,2,4-triazol-1-yl]-[4-(dimethylamino)phenyl]methanone Chemical compound C1=CC(N(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(=CC=2)N2CCN(C)CC2)=N1 FHOIHBNTAWYUMB-UHFFFAOYSA-N 0.000 claims 1
- HUSFYRCJIYIBNM-UHFFFAOYSA-N [5-amino-3-[4-(4-methylpiperazin-1-yl)anilino]-1,2,4-triazol-1-yl]-[4-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NN(C(=O)C=2C=CC(OC(C)(C)C)=CC=2)C(N)=N1 HUSFYRCJIYIBNM-UHFFFAOYSA-N 0.000 claims 1
- NFWQXJAPMJBITG-UHFFFAOYSA-N [5-amino-3-[4-[2-(1,3-dioxolan-2-yl)ethoxy]anilino]-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCC3OCCO3)=CC=2)=N1 NFWQXJAPMJBITG-UHFFFAOYSA-N 0.000 claims 1
- AGFVIAPXMFSUAD-UHFFFAOYSA-N [5-amino-3-[4-[2-(2,3-dihydro-1h-isoindol-1-yl)ethoxy]anilino]-1,2,4-triazol-1-yl]-(1h-indol-6-yl)methanone Chemical compound C1=C2C=CNC2=CC(C(=O)N2N=C(NC=3C=CC(OCCC4C5=CC=CC=C5CN4)=CC=3)N=C2N)=C1 AGFVIAPXMFSUAD-UHFFFAOYSA-N 0.000 claims 1
- MCNIHHXFAXQFSA-UHFFFAOYSA-N [5-amino-3-[4-[2-(2,3-dihydro-1h-isoindol-1-yl)ethoxy]anilino]-1,2,4-triazol-1-yl]-(4-morpholin-4-ylphenyl)methanone Chemical compound NC1=NC(NC=2C=CC(OCCC3C4=CC=CC=C4CN3)=CC=2)=NN1C(=O)C(C=C1)=CC=C1N1CCOCC1 MCNIHHXFAXQFSA-UHFFFAOYSA-N 0.000 claims 1
- GQOYUEBZDSPFPQ-UHFFFAOYSA-N [5-amino-3-[4-[2-(2,3-dihydro-1h-isoindol-1-yl)ethoxy]anilino]-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCC3C4=CC=CC=C4CN3)=CC=2)=N1 GQOYUEBZDSPFPQ-UHFFFAOYSA-N 0.000 claims 1
- GPJCXBGHNUNIDL-UHFFFAOYSA-N [5-amino-3-[4-[2-(azepan-1-yl)ethoxy]anilino]-1,2,4-triazol-1-yl]-(1h-indol-6-yl)methanone Chemical compound N=1N(C(=O)C=2C=C3NC=CC3=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCCCC1 GPJCXBGHNUNIDL-UHFFFAOYSA-N 0.000 claims 1
- YMGVFBIXLYEEPG-UHFFFAOYSA-N [5-amino-3-[4-[2-(azepan-1-yl)ethoxy]anilino]-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCCCC3)=CC=2)=N1 YMGVFBIXLYEEPG-UHFFFAOYSA-N 0.000 claims 1
- FBOSCOFUSXSJFR-UHFFFAOYSA-N [5-amino-3-[4-[2-(azepan-1-yl)ethoxy]anilino]-1,2,4-triazol-1-yl]-(4-tert-butylphenyl)methanone Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCCCC3)=CC=2)=N1 FBOSCOFUSXSJFR-UHFFFAOYSA-N 0.000 claims 1
- WOSXALFTTCGOIZ-UHFFFAOYSA-N [5-amino-3-[4-[2-(azepan-1-yl)ethoxy]anilino]-1,2,4-triazol-1-yl]-[4-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound C1=CC(OC(C)(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCCCC3)=CC=2)=N1 WOSXALFTTCGOIZ-UHFFFAOYSA-N 0.000 claims 1
- CMLKIUVKPPNMTF-UHFFFAOYSA-N [5-amino-3-[4-[2-(dimethylamino)ethoxy]anilino]-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(OCCN(C)C)=CC=C1NC1=NN(C(=O)C=2C=CC(C)=CC=2)C(N)=N1 CMLKIUVKPPNMTF-UHFFFAOYSA-N 0.000 claims 1
- RTLULVTVVBDSDM-UHFFFAOYSA-N [5-amino-3-[4-[2-(dimethylamino)ethoxy]anilino]-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN(C)C)=CC=2)=N1 RTLULVTVVBDSDM-UHFFFAOYSA-N 0.000 claims 1
- LBBHRIGBOUDBRS-UHFFFAOYSA-N [5-amino-3-[4-[2-(dimethylamino)ethoxy]anilino]-1,2,4-triazol-1-yl]-[4-(dimethylamino)phenyl]methanone Chemical compound C1=CC(OCCN(C)C)=CC=C1NC1=NN(C(=O)C=2C=CC(=CC=2)N(C)C)C(N)=N1 LBBHRIGBOUDBRS-UHFFFAOYSA-N 0.000 claims 1
- SBYOFFSKGSUHND-UHFFFAOYSA-N [5-amino-3-[4-[2-(dimethylamino)ethoxy]anilino]-1,2,4-triazol-1-yl]-[4-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound C1=CC(OCCN(C)C)=CC=C1NC1=NN(C(=O)C=2C=CC(OC(C)(C)C)=CC=2)C(N)=N1 SBYOFFSKGSUHND-UHFFFAOYSA-N 0.000 claims 1
- DOAOXLBNDMKROY-UHFFFAOYSA-N [5-amino-3-[4-[2-(dimethylamino)propoxy]anilino]-1,2,4-triazol-1-yl]-(4-propan-2-yloxyphenyl)methanone Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCC(C)N(C)C)=CC=2)=N1 DOAOXLBNDMKROY-UHFFFAOYSA-N 0.000 claims 1
- SWKQJEHGFYCCML-UHFFFAOYSA-N [5-amino-3-[4-[2-(dimethylamino)propoxy]anilino]-1,2,4-triazol-1-yl]-[4-(dimethylamino)phenyl]methanone Chemical compound C1=CC(OCC(C)N(C)C)=CC=C1NC1=NN(C(=O)C=2C=CC(=CC=2)N(C)C)C(N)=N1 SWKQJEHGFYCCML-UHFFFAOYSA-N 0.000 claims 1
- MUQZHQIPUVMVNR-UHFFFAOYSA-N [5-amino-3-[4-[2-(dimethylamino)propoxy]anilino]-1,2,4-triazol-1-yl]-[4-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound C1=CC(OCC(C)N(C)C)=CC=C1NC1=NN(C(=O)C=2C=CC(OC(C)(C)C)=CC=2)C(N)=N1 MUQZHQIPUVMVNR-UHFFFAOYSA-N 0.000 claims 1
- XULOGEQBAXOQEB-KRWDZBQOSA-N [5-amino-3-[4-[2-[(3s)-3-fluoropyrrolidin-1-yl]ethoxy]anilino]-1,2,4-triazol-1-yl]-(1h-indol-6-yl)methanone Chemical compound N=1N(C(=O)C=2C=C3NC=CC3=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CC[C@H](F)C1 XULOGEQBAXOQEB-KRWDZBQOSA-N 0.000 claims 1
- CGGDXBVNKUMGTM-INIZCTEOSA-N [5-amino-3-[4-[2-[(3s)-3-fluoropyrrolidin-1-yl]ethoxy]anilino]-1,2,4-triazol-1-yl]-(2,3-dihydro-1,4-benzodioxin-6-yl)methanone Chemical compound N=1N(C(=O)C=2C=C3OCCOC3=CC=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CC[C@H](F)C1 CGGDXBVNKUMGTM-INIZCTEOSA-N 0.000 claims 1
- NKMYMZZVJYWLMK-KRWDZBQOSA-N [5-amino-3-[4-[2-[(3s)-3-fluoropyrrolidin-1-yl]ethoxy]anilino]-1,2,4-triazol-1-yl]-[4-(dimethylamino)phenyl]methanone Chemical compound C1=CC(N(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3C[C@@H](F)CC3)=CC=2)=N1 NKMYMZZVJYWLMK-KRWDZBQOSA-N 0.000 claims 1
- XLEJTDFDSNDDOA-SFHVURJKSA-N [5-amino-3-[4-[2-[(3s)-3-fluoropyrrolidin-1-yl]ethoxy]anilino]-1,2,4-triazol-1-yl]-[4-[(2-methylpropan-2-yl)oxy]phenyl]methanone Chemical compound C1=CC(OC(C)(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3C[C@@H](F)CC3)=CC=2)=N1 XLEJTDFDSNDDOA-SFHVURJKSA-N 0.000 claims 1
- DGSVYYMCDPETKA-UHFFFAOYSA-N [5-amino-3-[4-[3-(dimethylamino)propoxy]anilino]-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(OCCCN(C)C)=CC=C1NC1=NN(C(=O)C=2C=CC(C)=CC=2)C(N)=N1 DGSVYYMCDPETKA-UHFFFAOYSA-N 0.000 claims 1
- BYJZHXOTFQRQKF-UHFFFAOYSA-N [5-amino-3-[[2-(oxan-2-yloxymethyl)-1-benzofuran-5-yl]amino]-1,2,4-triazol-1-yl]-(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)N2C(=NC(NC=3C=C4C=C(COC5OCCCC5)OC4=CC=3)=N2)N)=C1 BYJZHXOTFQRQKF-UHFFFAOYSA-N 0.000 claims 1
- OHLSVDKURRPCMA-UHFFFAOYSA-N [5-amino-3-[n-(2-hydroxyethoxy)anilino]-1,2,4-triazol-1-yl]-(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)N2C(=NC(=N2)N(OCCO)C=2C=CC=CC=2)N)=C1 OHLSVDKURRPCMA-UHFFFAOYSA-N 0.000 claims 1
- 125000004533 benzofuran-5-yl group Chemical group O1C=CC2=C1C=CC(=C2)* 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- RPSYDJLGXZBKTR-UHFFFAOYSA-N methyl 2-[3-[[5-amino-1-(3-methylbenzoyl)-1,2,4-triazol-3-yl]amino]phenoxy]acetate Chemical compound COC(=O)COC1=CC=CC(NC2=NN(C(N)=N2)C(=O)C=2C=C(C)C=CC=2)=C1 RPSYDJLGXZBKTR-UHFFFAOYSA-N 0.000 claims 1
- RZELWGOKESWMKX-UHFFFAOYSA-N methyl 2-[3-[[5-amino-1-(4-propan-2-yloxybenzoyl)-1,2,4-triazol-3-yl]amino]phenoxy]acetate Chemical compound COC(=O)COC1=CC=CC(NC2=NN(C(N)=N2)C(=O)C=2C=CC(OC(C)C)=CC=2)=C1 RZELWGOKESWMKX-UHFFFAOYSA-N 0.000 claims 1
- HRHUEZYMNYVRKZ-UHFFFAOYSA-N methyl 2-[4-[[5-amino-1-(4-propan-2-yloxybenzoyl)-1,2,4-triazol-3-yl]amino]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OC)=CC=C1NC1=NN(C(=O)C=2C=CC(OC(C)C)=CC=2)C(N)=N1 HRHUEZYMNYVRKZ-UHFFFAOYSA-N 0.000 claims 1
- MWKVKSICXMIXCE-UHFFFAOYSA-N methyl 3-[5-amino-3-[4-(2-piperidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carbonyl]benzoate Chemical compound COC(=O)C1=CC=CC(C(=O)N2C(=NC(NC=3C=CC(OCCN4CCCCC4)=CC=3)=N2)N)=C1 MWKVKSICXMIXCE-UHFFFAOYSA-N 0.000 claims 1
- WFEVFIDXUMSSRB-UHFFFAOYSA-N n-[4-[5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carbonyl]phenyl]-2,2-dimethylpropanamide Chemical compound C1=CC(NC(=O)C(C)(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCC3)=CC=2)=N1 WFEVFIDXUMSSRB-UHFFFAOYSA-N 0.000 claims 1
- MEXNIACOWQTXMF-UHFFFAOYSA-N n-[5-amino-1-(3-methylbenzoyl)-1,2,4-triazol-3-yl]-n-[3-[4-(2-chloro-6-fluorophenyl)piperazin-1-yl]propyl]-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)N(CCCN2CCN(CC2)C=2C(=CC=CC=2F)Cl)C2=NN(C(N)=N2)C(=O)C=2C=C(C)C=CC=2)=C1 MEXNIACOWQTXMF-UHFFFAOYSA-N 0.000 claims 1
- JGNUEHAWRGWWMP-UHFFFAOYSA-N n-phenyl-1,2,4-triazol-1-amine Chemical compound C1=NC=NN1NC1=CC=CC=C1 JGNUEHAWRGWWMP-UHFFFAOYSA-N 0.000 claims 1
- JFNLZVQOOSMTJK-UHFFFAOYSA-N norbornene Chemical compound C1C2CCC1C=C2 JFNLZVQOOSMTJK-UHFFFAOYSA-N 0.000 claims 1
- AFNNIHIBTGXLNY-UHFFFAOYSA-N tert-butyl 5-amino-3-(4-piperidin-1-ylanilino)-1,2,4-triazole-1-carboxylate Chemical compound N1=C(N)N(C(=O)OC(C)(C)C)N=C1NC1=CC=C(N2CCCCC2)C=C1 AFNNIHIBTGXLNY-UHFFFAOYSA-N 0.000 claims 1
- FIVTXGSTVPHMFT-UHFFFAOYSA-N tert-butyl n-[4-[5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carbonyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCC3)=CC=2)=N1 FIVTXGSTVPHMFT-UHFFFAOYSA-N 0.000 claims 1
- DHGXKEQQMGHMBH-UHFFFAOYSA-N tert-butyl n-[[4-[5-amino-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-triazole-1-carbonyl]phenyl]methyl]carbamate Chemical compound C1=CC(CNC(=O)OC(C)(C)C)=CC=C1C(=O)N1C(N)=NC(NC=2C=CC(OCCN3CCCC3)=CC=2)=N1 DHGXKEQQMGHMBH-UHFFFAOYSA-N 0.000 claims 1
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 abstract description 4
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 abstract description 2
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 50
- 125000004432 carbon atom Chemical group C* 0.000 description 24
- 150000003254 radicals Chemical class 0.000 description 17
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 125000001183 hydrocarbyl group Chemical group 0.000 description 7
- 125000000464 thioxo group Chemical group S=* 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000003446 ligand Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101150022345 GAS6 gene Proteins 0.000 description 3
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000003852 triazoles Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 101150098329 Tyro3 gene Proteins 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical class NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000002090 Fibronectin type III Human genes 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100031487 Growth arrest-specific protein 6 Human genes 0.000 description 1
- 101000650322 Homo sapiens E3 ubiquitin-protein ligase Arkadia Proteins 0.000 description 1
- 101000923005 Homo sapiens Growth arrest-specific protein 6 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 102000005608 Neuronal Cell Adhesion Molecules Human genes 0.000 description 1
- 108010059604 Neuronal Cell Adhesion Molecules Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 229910001573 adamantine Inorganic materials 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000008850 allosteric inhibition Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000005015 aryl alkynyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000005875 benzo[b][1,4]dioxepinyl group Chemical group 0.000 description 1
- 125000005876 benzo[b][1,4]oxazinyl group Chemical group 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000005020 hydroxyalkenyl group Chemical group 0.000 description 1
- 125000005016 hydroxyalkynyl group Chemical group 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940116353 sebacic acid Drugs 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000005985 thienyl[1,3]dithianyl group Chemical group 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71467305P | 2005-09-07 | 2005-09-07 | |
| US78016606P | 2006-03-07 | 2006-03-07 | |
| US81314306P | 2006-06-12 | 2006-06-12 | |
| PCT/US2006/034970 WO2007030680A2 (en) | 2005-09-07 | 2006-09-07 | Triazole derivatives useful as axl inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009507080A true JP2009507080A (ja) | 2009-02-19 |
| JP2009507080A5 JP2009507080A5 (enExample) | 2009-10-22 |
Family
ID=37622141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008530213A Pending JP2009507080A (ja) | 2005-09-07 | 2006-09-07 | Axl阻害剤として有用なトリアゾール誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US7884119B2 (enExample) |
| EP (1) | EP1922310A2 (enExample) |
| JP (1) | JP2009507080A (enExample) |
| CA (1) | CA2621503C (enExample) |
| WO (1) | WO2007030680A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015525743A (ja) * | 2012-07-06 | 2015-09-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 抗ウイルス剤としてのトリアゾール化合物 |
| JP2016505056A (ja) * | 2013-01-23 | 2016-02-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 抗ウイルス性トリアゾール誘導体 |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
| PL2114955T3 (pl) | 2006-12-29 | 2013-06-28 | Rigel Pharmaceuticals Inc | Triazole podstawione mostkowanym bicyklicznym arylem oraz mostkowanym bicyklicznym heteroarylem użyteczne jako inhibitory Axl |
| CA2710043C (en) | 2006-12-29 | 2016-02-09 | Rigel Pharmaceuticals, Inc. | Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| CN101622252B (zh) | 2006-12-29 | 2015-04-22 | 里格尔制药公司 | 用作axl抑制剂的取代三唑 |
| ES2607065T3 (es) * | 2006-12-29 | 2017-03-29 | Rigel Pharmaceuticals, Inc. | Triazoles N3-heteroaril sustituidos y triazoles N5-heteroaril sustituidos útiles como inhibidores de axl |
| ME01832B (me) | 2006-12-29 | 2014-12-20 | Rigel Pharmaceuticals Inc | Policiklični heteroaril supstituisani triazoli koji su korisni kao axl inhibitori |
| CA2692320A1 (en) * | 2007-07-02 | 2009-01-08 | Wyeth | Methods of treating bone disorders with modulators of axl |
| JP5635909B2 (ja) * | 2007-10-26 | 2014-12-03 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Axl阻害剤として有用な多環アリール置換トリアゾール及び多環ヘテロアリール置換トリアゾール |
| WO2010008411A1 (en) | 2007-11-09 | 2010-01-21 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors |
| BRPI0820543A2 (pt) | 2007-11-15 | 2015-06-16 | Chugai Pharmaceutical Co Ltd | Anticorpo monoclonal capaz de ligar a anexelekto, e uso do mesmo |
| HRP20170317T1 (hr) | 2008-02-15 | 2017-04-21 | Rigel Pharmaceuticals, Inc. | Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza |
| CA2730231C (en) | 2008-07-09 | 2016-10-18 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| CA2730251C (en) | 2008-07-09 | 2016-08-09 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| JP4644273B2 (ja) * | 2008-07-15 | 2011-03-02 | 本田技研工業株式会社 | 車両周辺監視装置 |
| CN105399731A (zh) * | 2008-12-24 | 2016-03-16 | 比亚尔-珀特拉和Ca股份公司 | 药物化合物 |
| BRPI1007046B1 (pt) * | 2009-01-16 | 2019-07-16 | Rigel Pharmaceuticals, Inc. | Inibidores axl para uso em terapia de combinação para evitar, tratar ou controlar o câncer metastático. |
| CA3207599A1 (en) | 2010-05-18 | 2011-11-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
| US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| BR112013020220B1 (pt) | 2011-02-09 | 2020-03-17 | Natera, Inc. | Método para determinar o estado de ploidia de um cromossomo em um feto em gestação |
| PT2810937T (pt) | 2012-01-31 | 2017-03-03 | Daiichi Sankyo Co Ltd | Derivado de piridona |
| WO2014018535A1 (en) | 2012-07-25 | 2014-01-30 | Salk Institute For Biological Studies | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine |
| US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
| CN105916506B (zh) | 2013-11-20 | 2020-01-07 | 圣诺康生命科学公司 | 作为tam家族激酶抑制剂的喹唑啉衍生物 |
| WO2015081257A2 (en) | 2013-11-27 | 2015-06-04 | Signalchem Lifesciences Corporation | Aminopyridine derivatives as tam family kinase inhibitors |
| US20150252370A1 (en) * | 2014-03-04 | 2015-09-10 | Academia Sinica | Use of atx inhibitors for treatment or prevention of influenza virus a infections |
| EP3134541B1 (en) | 2014-04-21 | 2020-08-19 | Natera, Inc. | Detecting copy number variations (cnv) of chromosomal segments in cancer |
| US20180173846A1 (en) | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
| TWI723572B (zh) | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
| US11479812B2 (en) | 2015-05-11 | 2022-10-25 | Natera, Inc. | Methods and compositions for determining ploidy |
| GB201509338D0 (en) | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
| ES2896079T3 (es) | 2016-02-26 | 2022-02-23 | Ono Pharmaceutical Co | Fármaco para la terapia del cáncer, caracterizado por la administración de la combinación entre un inhibidor de Axl y un inhibidor del punto de control inmunitario |
| RU2760913C2 (ru) | 2016-04-15 | 2021-12-01 | Натера, Инк. | Способы выявления рака легкого |
| WO2018067517A1 (en) | 2016-10-04 | 2018-04-12 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
| GB201618485D0 (en) | 2016-11-02 | 2016-12-14 | Ucl Business Plc | Method of detecting tumour recurrence |
| US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
| US20200197385A1 (en) | 2017-08-23 | 2020-06-25 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for cancer containing axl inhibitor as active ingredient |
| US11826363B2 (en) | 2017-10-13 | 2023-11-28 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient |
| US12084720B2 (en) | 2017-12-14 | 2024-09-10 | Natera, Inc. | Assessing graft suitability for transplantation |
| US12024738B2 (en) | 2018-04-14 | 2024-07-02 | Natera, Inc. | Methods for cancer detection and monitoring |
| US12234509B2 (en) | 2018-07-03 | 2025-02-25 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| CA3123847A1 (en) | 2018-12-17 | 2020-06-25 | Natera, Inc. | Methods for analysis of circulating cells |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| WO2020247263A1 (en) | 2019-06-06 | 2020-12-10 | Natera, Inc. | Methods for detecting immune cell dna and monitoring immune system |
| PH12022550361A1 (en) | 2019-08-14 | 2023-02-27 | Incyte Corp | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
| PE20221905A1 (es) | 2019-10-11 | 2022-12-23 | Incyte Corp | Aminas biciclicas como inhibidoras de la cdk2 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
| JP2023521753A (ja) | 2020-04-08 | 2023-05-25 | ベルゲンビオ アーエスアー | 抗ウイルス療法 |
| GB202006072D0 (en) | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
| GB202104037D0 (en) | 2021-03-23 | 2021-05-05 | Bergenbio Asa | Combination therapy |
| AU2022261868A1 (en) | 2021-04-22 | 2023-10-26 | Natera, Inc. | Methods for determining velocity of tumor growth |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US20240336973A1 (en) | 2021-08-02 | 2024-10-10 | Natera, Inc. | Methods for detecting neoplasm in pregnant women |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CN119032182A (zh) | 2022-01-04 | 2024-11-26 | 纳特拉公司 | 用于癌症检测和监测的方法 |
| GB202209285D0 (en) | 2022-06-24 | 2022-08-10 | Bergenbio Asa | Dosage regimen for AXL inhibitor |
| WO2024051667A1 (zh) * | 2022-09-05 | 2024-03-14 | 南京正大天晴制药有限公司 | 具有axl抑制活性的取代三唑化合物 |
| WO2024054793A1 (en) | 2022-09-09 | 2024-03-14 | University Of Rochester | Inhibition of efferocytosis as a treatment to prevent bone loss and increase bone density and strength |
| WO2024218236A1 (en) * | 2023-04-18 | 2024-10-24 | Centre National De La Recherche Scientifique | 3,5-diaminotriazole derivatives and uses thereof for treating ocular diseases |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07101942A (ja) * | 1993-07-23 | 1995-04-18 | Green Cross Corp:The | 新規トリアゾール誘導体 |
| WO2002057240A1 (en) * | 2000-12-22 | 2002-07-25 | Ortho Mc Neil Pharmaceutical, Inc. | Substituted triazole diamine derivatives as kinase inhibitors |
| JP2003506362A (ja) * | 1999-08-02 | 2003-02-18 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Gsk−3阻害剤としてのジアミノ−1,2,4−トリアゾール−カルボン酸誘導体 |
| WO2004046120A2 (en) * | 2002-11-15 | 2004-06-03 | Vertex Pharmaceuticals Incorporated | Diaminotriazoles useful as inhibitors of protein kinases |
| JP2005504101A (ja) * | 2001-09-27 | 2005-02-10 | アルコン,インコーポレイテッド | 緑内障を治療するためのグリコゲンシンターゼキナーゼ−3(gsk−3)インヒビター |
| WO2005077922A2 (en) * | 2004-02-11 | 2005-08-25 | Janssen Pharmaceutica, N.V. | Process for the preparation of substituted triazole compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1403866A (en) * | 1971-12-06 | 1975-08-28 | Wyeth John & Brother Ltd | Derivatives of 3-amino-1,2,4-triazoles |
| US5750545A (en) | 1993-07-23 | 1998-05-12 | The Green Cross Corporation | Triazole derivative and pharmaceutical use thereof |
| MXPA04010778A (es) | 2002-05-03 | 2005-03-07 | Janssen Pharmaceutica Nv | Microemulsiones polimericas. |
| CN100345593C (zh) | 2002-08-06 | 2007-10-31 | 东丽株式会社 | 用于制备肾脏疾病的治疗或预防药物中的用途 |
| US8574827B2 (en) * | 2002-10-29 | 2013-11-05 | Rigel Pharmaceuticals, Inc. | Modulators of angiogenesis and tumorigenesis |
| AR045731A1 (es) | 2003-08-06 | 2005-11-09 | Vertex Pharma | Compuestos de aminotriazol utiles como inhibidores de quinasas de proteinas |
| ES2607065T3 (es) * | 2006-12-29 | 2017-03-29 | Rigel Pharmaceuticals, Inc. | Triazoles N3-heteroaril sustituidos y triazoles N5-heteroaril sustituidos útiles como inhibidores de axl |
| ME01832B (me) * | 2006-12-29 | 2014-12-20 | Rigel Pharmaceuticals Inc | Policiklični heteroaril supstituisani triazoli koji su korisni kao axl inhibitori |
| CN101622252B (zh) * | 2006-12-29 | 2015-04-22 | 里格尔制药公司 | 用作axl抑制剂的取代三唑 |
| PL2114955T3 (pl) * | 2006-12-29 | 2013-06-28 | Rigel Pharmaceuticals Inc | Triazole podstawione mostkowanym bicyklicznym arylem oraz mostkowanym bicyklicznym heteroarylem użyteczne jako inhibitory Axl |
| CA2710043C (en) * | 2006-12-29 | 2016-02-09 | Rigel Pharmaceuticals, Inc. | Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| WO2008157131A1 (en) | 2007-06-15 | 2008-12-24 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| JP5635909B2 (ja) * | 2007-10-26 | 2014-12-03 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Axl阻害剤として有用な多環アリール置換トリアゾール及び多環ヘテロアリール置換トリアゾール |
| CA2730231C (en) * | 2008-07-09 | 2016-10-18 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| CA2730251C (en) * | 2008-07-09 | 2016-08-09 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| BRPI1007046B1 (pt) * | 2009-01-16 | 2019-07-16 | Rigel Pharmaceuticals, Inc. | Inibidores axl para uso em terapia de combinação para evitar, tratar ou controlar o câncer metastático. |
-
2006
- 2006-09-07 WO PCT/US2006/034970 patent/WO2007030680A2/en not_active Ceased
- 2006-09-07 CA CA2621503A patent/CA2621503C/en not_active Expired - Fee Related
- 2006-09-07 EP EP20060814315 patent/EP1922310A2/en not_active Withdrawn
- 2006-09-07 US US11/518,550 patent/US7884119B2/en active Active
- 2006-09-07 JP JP2008530213A patent/JP2009507080A/ja active Pending
-
2010
- 2010-12-10 US US12/965,545 patent/US8389557B2/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07101942A (ja) * | 1993-07-23 | 1995-04-18 | Green Cross Corp:The | 新規トリアゾール誘導体 |
| JP2003506362A (ja) * | 1999-08-02 | 2003-02-18 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Gsk−3阻害剤としてのジアミノ−1,2,4−トリアゾール−カルボン酸誘導体 |
| WO2002057240A1 (en) * | 2000-12-22 | 2002-07-25 | Ortho Mc Neil Pharmaceutical, Inc. | Substituted triazole diamine derivatives as kinase inhibitors |
| JP2005504101A (ja) * | 2001-09-27 | 2005-02-10 | アルコン,インコーポレイテッド | 緑内障を治療するためのグリコゲンシンターゼキナーゼ−3(gsk−3)インヒビター |
| WO2004046120A2 (en) * | 2002-11-15 | 2004-06-03 | Vertex Pharmaceuticals Incorporated | Diaminotriazoles useful as inhibitors of protein kinases |
| WO2005077922A2 (en) * | 2004-02-11 | 2005-08-25 | Janssen Pharmaceutica, N.V. | Process for the preparation of substituted triazole compounds |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015525743A (ja) * | 2012-07-06 | 2015-09-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 抗ウイルス剤としてのトリアゾール化合物 |
| JP2016505056A (ja) * | 2013-01-23 | 2016-02-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 抗ウイルス性トリアゾール誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007030680A2 (en) | 2007-03-15 |
| US7884119B2 (en) | 2011-02-08 |
| CA2621503C (en) | 2014-05-20 |
| WO2007030680A3 (en) | 2007-05-18 |
| US20070213375A1 (en) | 2007-09-13 |
| US8389557B2 (en) | 2013-03-05 |
| CA2621503A1 (en) | 2007-03-15 |
| US20110082131A1 (en) | 2011-04-07 |
| EP1922310A2 (en) | 2008-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8389557B2 (en) | Triazole derivatives useful as Axl inhibitors | |
| CA3124898C (en) | Heterocyclic compound, intermediate, preparation method therefor and application thereof | |
| US8563559B2 (en) | Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors | |
| CA2710234C (en) | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | |
| US9458110B2 (en) | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors | |
| US7285554B2 (en) | Pyrazole derivative | |
| CN101636397B (zh) | 脲类化合物、其制备方法及其医药用途 | |
| JP5640002B2 (ja) | 抗腫瘍活性を有する、hsp90調節性5−フェニル−イソオキサゾール−3−カルボキシアミド | |
| US20060058329A1 (en) | Pyrazole inhibitors of the transforming growth factor | |
| JP2008526887A (ja) | カンナビノイド受容体に作用する新規なヘテロピロール類似体 | |
| JP2010514809A (ja) | Axlインヒビターとして有用なN3−ヘテロアリール置換トリアゾールおよびN5−ヘテロアリール置換トリアゾール | |
| KR20050044407A (ko) | N,n'-치환-1,3-디아미노-2-히드록시프로판 유도체 | |
| AU2006261841A1 (en) | Pyrazole based LXR modulators | |
| EA007720B1 (ru) | Производные триазола в качестве антагонистов рецептора тахикинина | |
| JP2011507848A (ja) | Rhoキナーゼインヒビターとしてのベンゾピランおよびアナログ | |
| JP2013534229A (ja) | バニロイド受容体リガンドとしての置換された環状カルボキサミド誘導体および尿素誘導体 | |
| JP2007522142A (ja) | Ikk3に対して活性を有するベンゾイミダゾール置換チオフェン誘導体 | |
| AU714701B2 (en) | Novel thiophene derivative and pharmaceutical composition thereof | |
| ES2330788T3 (es) | Derivados de piperidin-4-il-amida y su uso como antagonistas del subtipo 5 del receptor sst. | |
| WO2017024996A1 (zh) | 羟基脒类衍生物、其制备方法及其在医药上的应用 | |
| KR20000075697A (ko) | 5-ht2a-길항제로서의 옥사졸리딘 | |
| EA001217B1 (ru) | СЕЛЕКТИВНЫЕ β-АДРЕНЕРГИЧЕСКИЕ АГОНИСТЫ | |
| AU622291B2 (en) | (substituted (1,2,3,6-tetrahydropyrid-1-yl)alkyl or thio- alkyl)indoles | |
| AU2006316705B2 (en) | Urea derivatives useful as calcium receptor modulators | |
| ES2939730T3 (es) | Compuestos de heteroarilo de 5 miembros que contienen un resto hidroxamato y su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090904 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090904 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120417 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120417 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120918 |